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2. ABBREVIATIONS 
 
ATP adenosine triphosphate  
CNS central nervous system 
DCFDA 2′,7′-Dichlorofluorescin diacetate  
DHE dihydroethidium 
ERK extracellular signal-regulated kinase 
ETC electron transport chain 
GM-CSF growth macrophage colony stimulating factor 
HA histamine 
H2O2 hydrogen peroxide 
IFNγ interferon γ 
IL- interleukin 
IMM inner mitochondrial membrane 
IR ischemia reperfusion 
JNK c-Jun N-terminal kinase 
LDH lactate dehydrogenase 
LPS lipopolysaccharide 
MAO monoamine oxidase 
MAPK mitogen activated protein kinases 
M-CSF macrophage colony stimulating factor 
Mn monocytes  
MS mass spectrometry 
MTR mitotracker red 
MΦ macrophages 
NE norepinephrine 
NMH Nτ-methylhistamine 
NOX nicotinamide adenine dinucleotide phosphate oxidase 
NRVMs neonatal rat ventricular myocytes 
OMM outer mitochondrial membrane 
PEA phenylethylamine 
Pi phosphate 
PNS peripheral nervous system 
PTP permeability transition pore 
ROS reactive oxygen species 
SDS sodium dodecyl sulphate 
TNF-α tumor necrosis factor α 
5-HT serotonin 
15-LOX1 15-lipoxygenase 
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3. SUMMARY 
 
Mitochondria represent the main site of both ROS formation and degradation. 
One of the main source of mitochondrial ROS is represented by monoamine 
oxidases (MAOs). MAOs are flavoenzymes located in the outer mitochondrial 
membrane, which catalyse the oxidative deamination of biogenic amines yielding 
aldehydes, ammonia, and hydrogen peroxide (H2O2). It has been demonstrated 
that these products contribute to the oxidative stress occurring in hearts 
subjected to pathological conditions, such as cardiac reperfusion injury and 
decompensated hypertrophy. As MAO inhibitors significantly protect the heart in 
these models of cardiac injury, we focused our attention on the molecular 
mechanisms underlying MAO activation. To address this issue we investigated (i) 
the availability of MAO substrates under conditions of oxidative stress or injury 
and (ii) their main cellular sources in the whole heart. By mass spectrometry 
(MS) analysis we identified several amines that became available upon different 
ex vivo protocols of cardiac injury, and we focused our attention on Nτ-
methylhistamine (NMH) and its precursor histamine, which were found the most 
abundant. Thus, we evaluated the contribution of myocyte and non-myocyte 
cells as possible sources of MAO substrates. For this purpose we firstly excluded 
synaptic terminals that innervate heart by mice injection of a neurotoxin, 6-
hydroxydopamine (6-OH-DOPA). Our findings demonstrate the relevant 
contribution of synaptic terminals to increase the availability of MAO substrates 
in the ex vivo model of oxidative stress. Next we considered isolated 
cardiomyocytes, as these cells undergo MAO-dependent oxidative stress. We 
showed that cardiomyocytes can synthesize MAO substrates and to induce MAO 
activity when exposed to oxidative stress. Taken together, we establish for the 
first time a relevant interaction between histamine metabolism and MAO activity 
in cardiac injury, that does not involve a receptor-dependent pathway. These 
findings can explain how MAO activity is turned on when cells are stressed. 
Moreover, it also helps understanding how the increase in MAO activity amplifies 
an initial oxidative stress.  
It has been largely shown that inflammation is usually involved in cardiac 
diseases and monocytes (Mn), macrophages (MΦ) as well as mast cells are 
involved in the inflammatory response. We focused our attention on immune 
phagocytic cells since the role of MAO has not been conclusively defined. Firstly, 
we demonstrated that both the MAO isoforms were expressed in both M1 and 
M2 MΦ. We focused our attention on MAO A, as it resulted the most expressed 
and significant isoform, especially in M2 MΦ. Then, we characterized its pathway 
of induction considering two different stimuli: LPS, that is a pro-inflammatory 
signal and IL-4 plus IL-13 (IL-4+IL-13), that is a combination of anti-
inflammatory cytokines. 
It is well known that during differentiation and polarization MΦ generate ROS, 
which leads to the activation of different signalling pathways. However, the 
mechanisms that induce ROS formation and activate this signalling remain 
unclear. Here we demonstrated that MAO contributes to macrophage 
differentiation and polarization through its H2O2 production. 
Taken together, these data demonstrate for the first time that MAO-A plays a role 
in M2 MΦ differentiation and activation, besides its role in amine oxidative 
degradation. These novel insights about MAO activity in phagocytic cells suggest 
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that this enzyme could represent a new target to modulate MΦ differentiation 
and activation under pathological conditions to avoid the side effects related to 
inflammation such as fibrosis, cardiac remodelling, and oxidative stress 
amplification in post-ischemic reperfusion injury. 
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3.1 SOMMARIO 
 
I mitocondri rappresentano il sito principale di origine e smaltimento delle 
specie reattive dell’ossigeno (ROS). Una delle più importanti fonti mitocondriali 
di ROS è rappresentata dalle monoammino ossidasi (MAO). Le MAO sono 
flavoenzimi situati nella membrana mitocondriale esterna, che catalizzano la 
deaminazione ossidativa di ammine biogeniche, producendo aldeidi, ammoniaca 
e perossido d’idrogeno (H2O2). È stato dimostrato che questi prodotti 
contribuiscono allo stress ossidativo che si verifica in cuori soggetti a condizioni 
patologiche, come ad esempio l’ischemia riperfusione e lo scompenso da 
ipertrofia. Dato che gli inibitori per le MAO proteggono significativamente il 
cuore in questi modelli di danno cardiaco, abbiamo focalizzato la nostra 
attenzione sui meccanismi molecolari alla base dell’attivazione di questi enzimi. 
A questo scopo è stata analizzata (i) la disponibilità dei substrati per le MAO in 
condizioni di stress ossidativo o danno cardiaco, e sono state valutate (ii) le 
principali fonti cellulari per questi substrati nel cuore. Mediante spettrometria di 
massa (MS) sono state identificate diverse ammine, rese disponibili in due 
differenti protocolli sperimentali d’induzione di stress cardiaco ex vivo. 
Particolare attenzione è stata data alla Nτ-Metilistamina (NMH) ed il suo 
precursore istamina, che rappresentavano la maggiore frazione di ammine sul 
contenuto totale nel cuore in queste condizioni di stress. Quindi, è stato valutato 
il contributo delle cellule miocitiche e non, come possibili fonti di substrati per le 
MAO. Anzitutto sono stati considerati i terminali sinaptici che innervano il cuore, 
e quindi eliminati iniettando gli animali con una neurotossina, la 6-
idrossidopamina (6-OH-DOPA). I risultati così ottenuti dimostrano il contributo 
dei terminali nell’aumentare la disponibilità di substrati per le MAO nel modello 
ex vivo sottoposto a stress ossidativo. Sucessivamente, abbiamo considerato i 
cardiomiociti isolati, in quanto anch’essi subiscono lo stress ossidativo 
dipendente dalle MAO. Infatti abbiamo dimostrato che i cardiomiociti soggetti a 
stress ossidativo sono in grado di sintetizzare substrati per le MAO, 
promuovendo l'attività dell’enzima. Si stabilisce così per la prima volta 
un’importante relazione tra il metabolismo dell’istamina e l'attività dell’enzima 
MAO in condizioni di danno cardiaco, la quale non comporta alcuna dipendenza 
da un eventuale recettore istaminergico. Questi risultati spiegano come lo stress 
cellulare possa indurre l'attività enzimatica dell’enzima MAO amplificando 
l’iniziale stress ossidativo. 
È stato ampiamente dimostrato che l'infiammazione insorge durante le malattie 
cardiache e non solo, inoltre che le cellule infiammatorie coinvolte come 
monociti (Mn), macrofagi (MΦ) e mastociti sono particolarmente rilevanti ed 
attive. Pertanto la nostra attenzione è stata incentrata dalle cellule fagocitarie in 
cui il ruolo dell’enzima MAO non è stato ancora definito. In primo luogo, è stato 
dimostrato che entrambe le isoforme MAO (A e B) sono espresse sia nei MΦ M1 
che M2. Poi ci siamo focalizzati su MAO A, in quanto è risultata essere l'isoforma 
principalmente espressa, soprattutto nei MΦ M2. In seguito è stato 
caratterizzato il suo meccanismo d’induzione, considerando due diversi stimoli: 
l’LPS e la combinazione delle citochine anti-infiammatorie IL-4 ed IL-13 (IL-4 + 
IL-13). 
È noto che, durante i processi di differenziamento e di polarizzazione, i MΦ 
generino ROS, che inducono l'attivazione di diverse vie di segnale. Tuttavia, i 
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meccanismi che inducono la formazione di questi ROS non sono stati 
caratterizzati. 
In questo lavoro è stato dimostrato per la prima volta che l’isoforma A 
dell’enzima MAO svolge un ruolo rilevante nel differenziamento e 
nell’attivazione dei MΦ M2, mediante la produzione di H2O2. Questi nuovi 
risultati nelle cellule fagocitiche suggeriscono che questo enzima potrebbe 
rappresentare un nuovo bersaglio per modulare il differenziamento e 
l’attivazione dei MΦ. In particolare, in condizioni patologiche la loro 
modulazione potrebbe limitare gli effetti collaterali legati all’infiammazione, 
come ad esempio la fibrosi, il rimodellamento cardiaco, e l’amplificazione dello 
stress ossidativo nel danno da ischemia/riperfusione. 
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4. INTRODUCTION 
 
4.1 Reactive Oxygen Species (ROS) 
 
Oxygen represents an indispensable molecule for any aerobic organisms but it 
can become toxic when it is partially reduced. 
The complete reduction of O2 into two molecules of H2O requires four electrons. 
This process occurs sequentially, since O2 accepts only one electron at a time. 
Consequently, O2 reduction inevitably implies the formation of partially reduced 
intermediates. In particular, the addition of the first electron yields superoxide 
anion (O2·-) that becomes hydrogen peroxide (H2O2) when one additional 
electron is added. A further single electron reduction produces the hydroxyl 
radical (·OH) that accepting another electron becomes H2O. O2·- and ·OH are 
oxygen radicals (i.e, containing unpaired electrons) and represent quite reactive 
species. H2O2 is less reactive per se, but, according to the Fenton reaction, in the 
presence of Fe2+ or Cu+ generates ·OH. These partially reduced forms of oxygen 
are commonly referred to as ROS, which also include the highly reactive singlet 
oxygen (1O2). This excited form of oxygen is produced by the Haber–Weiss 
reaction (i.e, the non-enzymatic dismutation of O2·-) or high energy irradiation 
(i.e, UV light).  
ROS are produced at various intracellular sites, yet it is generally accepted that in 
cardiac myocytes the largest amount of ROS are formed within mitochondria.1, 2, 
3, 4, 5 Besides impairment of energy metabolism and ionic homeostasis, formation 
of ROS represents an additional process through which mitochondrial 
dysfunction accelerates, or even determines, the evolution of cell injury towards 
necrosis or apoptosis.6, 7, 8, 9, 10, 11 
 
4.2 Mitochondria as source and target of ROS  
 
Mitochondria are well known as the powerhouse of the cell, as they are 
responsible for generating most of the ATP in the cell, for their role of 
posttranslational modifications in the regulation of metabolism, for the 
regulation and role of mitochondrial matrix calcium. Mitochondria are also key 
regulators of cell death. In the process of electron transport to generate ATP, 
mitochondria can be a major source of reactive oxygen species (ROS) that can 
both contribute to cell death and serve as a signaling molecule.4, 12 
The large majority of oxygen delivered to mitochondria is fully reduced to water 
at the level of Complex IV. In this terminal step of the mitochondrial respiratory 
chain, oxygen is reduced sequentially, yet reaction intermediates remain bound 
to Complex IV, so that only the final product, i.e, water, is released. Nevertheless, 
electrons flowing through the respiratory chain can be donated to oxygen at 
other sites, but in these cases the reduction is not complete resulting in the 
release of partially reduced forms, especially superoxide anion. In fact, O2·- is 
formed at the level of Complex I and III and is then rapidly dismutated into H2O2 
by SOD.13 Besides the classical notion of the mitochondrial localization of MnSOD 
or SOD-2, also CuZnSOD (SOD-1), commonly referred to as the cytosolic isoform, 
is present in the intermembrane space of mitochondria.14 
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Mitochondrial ROS formation is favored by a decrease in electron flow resulting 
from respiratory chain inhibition and is counteracted by uncoupling that is 
generally produced by an increased IMM permeability to protons. This latter 
process explains the protective efficacy related to increased expression of 
uncoupling proteins (UCP), especially UCP2 and 3.15 The level of these proteins is 
suggested to remain below that required for reducing the inner mitochondrial 
membrane potential and ATP synthesis, so that the most relevant effect would 
remain a decrease in ROS formation. However, despite the large body of 
evidence supporting the cardioprotective role of UCPs,15 negative results have 
also been associated with UCP2 overexpression in cardiomyocytes.16 
Nitric oxide (NO·) is a free radical that might modulate mitochondrial ROS 
formation by inhibiting cytochrome oxidase.5, 17, 18, 19 This reversible process can 
be transformed into irreversible alterations of respiratory chain when NO· 
formation is sustained. Indeed, NO· reacting with O2·- generates peroxynitrite, 
which can produce the irreversible nitration of proteins.20 Interestingly, a 
proteomic study showed that one-third of the proteins nitrated during 
inflammatory challenge are of mitochondrial origin.21 
It must be pointed out that ROS are also produced within mitochondria at sites 
other than the inner mitochondrial membrane, such as monoamine oxidase 
(MAO) and p66Shc (fig. 1). These additional mitochondrial processes produce 
significant amounts of ROS.22 For instance, in brain mitochondria the highest rate 
of H2O2 formation from respiratory chain, as observed in the presence of the 
Complex III inhibitor antimycin A, is 48-fold lower than that originating from 
MAO activity. Therefore, generation of ROS, especially H2O2, far from being just 
an unfortunate side effect of respiration, is catalyzed by specific enzymes, such as 
MAO and p66Shc.23  
P66Shc is a vertebrate splice variant of p52Shc and p46Shc, two cytoplasmic 
adaptor proteins involved in the propagation of intracellular signals from 
activated tyrosine kinases to Ras.24 Studies carried out in a wide range of 
experimental models demonstrated quite clearly that ROS formation is reduced 
in cells lacking p66Shc, and that systemic and intracellular markers of oxidative 
stress are diminished in p66Shc -/- mice.25, 26, 27, 28 Indeed, ROS formation is 
directly enhanced by p66Shc that, translocating to mitochondria, catalyzes an 
alternative redox reaction.27 In particular, electrochemical experiments 
demonstrated that the amino terminal portion of p66Shc contains a redox active 
sequence able to couple the reduction of molecular oxygen to H2O2 with the 
oxidation of cytochrome c.27 
MAOs are enzymes located in the outer mitochondrial membrane. They 
deaminate key neurotransmitters such as norepinephrine (NE), epinephrine, 
serotonin and dopamine, generating H2O2 alongside.29 All these monoamines are 
endowed with potent modulatory effects on myocardial function. Thus, when the 
heart is subjected to chronic stress, the abundance of circulating/tissue 
monoamines can make MAO-derived H2O2 production particularly prominent. 
This is the case of acute cardiac damage due to ischemia/reperfusion injury or, 
on a more chronic stand, of the transition from compensated hypertrophy to 
overt ventricular dilation/pump failure.  
More recently, the list of mitochondrial sources of ROS has been added with 
NADPH oxidase 4 (NOX4) (fig. 1), suggesting its contribution in oxidative stress 
and heart failure.30 However, evidence has also been provided that NOX4 is 
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localized to the ER and mediates protection against chronic load-induced stress 
by enhancing angiogenesis.11, 31 
 
 
 
Figure 1. Sources of ROS in mitochondria. From Di Lisa and Scorrano, Mitochondrial 
Morphology and Function, Muscle-Fundamental biology and mechanisms of disease, 2012. 11 
 
4.3 Mitochondrial dysfunction in cardiac disease 
 
The tight dependence of myocardial metabolism and function on oxygen 
consumption is clearly indicated by the abundance of mitochondria that occupy 
more than one-third of the cardiomyocyte volume. 
One of the major link between mitochondria and vascular derangements is 
oxidative stress.32, 33, 34, 35, 36 In particular, the development of atherosclerosis 
appears to depend on the mitochondrial metabolism of ROS. In fact, when 
mitochondrial antioxidant defenses are hampered, atherosclerosis is 
exacerbated, whereas a decrease in mitochondrial ROS formation reduces 
atherogenesis.36 For instance, the absence of SOD-2 increases mtDNA damage 
and accelerates atherosclerosis in apoE knockout mice.37 These findings are 
consistent with results obtained in ischemia/reperfusion experiments, which 
show that SOD-2 overexpression elicits cardioprotection,38 whereas a 
heterozygous deficiency of this enzyme impairs postischemic recovery of the 
heart.39 
In addition to the damage to all the cellular components, oxidative stress 
increases the occurrence of cell death, especially by apoptosis, which greatly 
contributes to the progress of atherosclerotic lesions. In this respect, an 
important consequence of ROS accumulation is an increased susceptibility to 
opening of the mitochondrial permeability transition pore (PTP).40 PTP opening 
is especially sensitive to oxidative stress, since it is favored by decreases in 
NADPH(H+)/NADP+ and -SH/-S-S ratios.41, 42 Recent evidence suggests that PTP 
opening and ROS formation are linked in a vicious cycle. In addition to being a 
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likely consequence of oxidative stress, PTP opening has been shown to increase 
mitochondrial ROS formation in cardiac myocytes.43 
Despite the large body of evidence that relates PTP opening to cell death, 
especially in the case of an ischemia/reperfusion injury to the heart44 definitive 
proof of PTP involvement in atherogenesis is lacking. 
While data obtained in vitro indicate that PTP opening causes cell death in 
isolated endothelial and vascular smooth muscle cells33, 45 no information on the 
effect of pharmacological or genetic inhibition of the PTP on atherogenesis in 
vivo is available.46, 47 
 
4.4 The ischemia/reperfusion injury of the heart 
 
In tissue subjected to ischemia followed by reperfusion (IR), pathologic 
mechanisms are elicited and produce reversible cell injury and dysfunction, 
which can progress to irreversible damage if the nature and extent of ischemia is 
prolonged and/or amplified.44 
At a cellular level, the onset of ischemia is determined by an insufficient 
availability of oxygen for mitochondrial oxidations (fig. 2). As a consequence of 
the reduced or absent oxidative phosphorylation, intracellular creatine 
phosphate is rapidly depleted with a concomitant rise in Pi, both factors 
stimulating glycolysis and lactate formation. The accumulation of lactate and the 
hydrolysis of adenosine triphosphate (ATP) decrease intracellular pH. During the 
early phase of ischemia, the failure of contraction and the rigor contracture, 
which are the most relevant changes in myocardial function, are caused by 
intracellular acidosis and severe reduction in ATP content respectively. Besides 
these relevant functional changes, several cellular activities are modified by the 
fall in pH and ATP content, including the inhibition of glycolysis which is 
observed under conditions of severe ischemia. 
A low pH and the accumulation of lactate decrease the activity of both 
phosphofructokinase (PFK) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). In addition, the fall in ATP is associated with membrane binding and 
inactivation of PFK. Thus, the failure in mitochondrial ATP production, which 
initially stimulates glycogen breakdown and glycolysis, is followed by the 
inhibition of glycolysis that is the only alternative pathway for ATP synthesis in 
anaerobic cells. 
Despite the arrest of the respiratory chain, the mitochondrial membrane 
potential is not immediately collapsed at the onset of ischemia. In fact, the 
mitochondrial membrane potential is maintained by the inverse operation of the 
F0F1 ATP synthase that uses ATP generated by glycolysis. Therefore, during 
ischemia not only do mitochondria cease to be the major ATP producers of the 
cell, but they can also become its major consumers. 
Prolongation of ischemia (i.e, more than 20 min of no-flow ischemia in perfused 
hearts) leads myocytes to a point of no return beyond which even readmission of 
oxygen fails to rescue cell viability. Myocardial tissue exhibits a peculiar 
transition from reversible to irreversible damage. In every cell type, the lack of 
ATP production and a severe decrease of its content result in a slow 
degenerative process that leads to the loss of plasma membrane integrity with 
release of intracellular components. Thus, if the initial pathological stimulus (i.e, 
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lack of oxygen) is not removed, the inhibition or the alteration of mitochondrial 
function results in cell death. In addition, the myocardium exhibits a peculiar 
transition to irreversible injury, which occurs suddenly when oxygen supply is 
re-established after a prolonged period of ischemia. In this case, the uncontrolled 
hypercontracture of myofilaments (fig. 2) is associated with a rapid increase in 
cell membrane permeability followed by the release of intracellular constituents. 
The sudden changes produced by reperfusion on myocardial viability are 
concomitant with massive accumulation of calcium within the mitochondrial 
matrix. Intracellular Ca2+ overload in myocardial pathology indicates that the 
rapid transition toward cell death requires a coupled mitochondrial respiration. 
In fact, respiratory chain inhibition or uncoupling of oxidative phosphorylation 
blunts enzyme release occurring at the onset of post-ischemic reperfusion. 
Therefore, oxidative phosphorylation not only is essential for cell recovery, but 
can also contribute to the processes causing cell necrosis. 
The apparent paradox linking mitochondrial function with cell death is related to 
the different ATP requirements of contraction and relaxation at the myofilament 
level. A suboptimal mitochondrial function could produce low levels of ATP 
which, in the presence of even a modest rise in [Ca2+]i, might be sufficient for the 
formation of rigor bonds but not for the relaxation process, resulting in 
myofilament hypercontracture. Supporting this concept, at reperfusion 
hypercontracture is abrogated not only by preventing oxidative 
phosphorylation, but also by inhibiting myosin ATPase. 
Regarding the causes of mitochondrial dysfunction, upon reperfusion 
mitochondria are exposed to high levels of Ca2+ that is increased in the cytosol 
due to both the failure of Ca2+ ATPases and uptake through the sarcolemma 
Na+/Ca2+ exchanger. Since mitochondrial Ca2+ uptake and ATP synthesis utilize 
the same driving force, namely the Dcm, mitochondrial Ca2+ accumulation results 
inevitably in a significant decrease in ATP formation. In addition and 
importantly, the rise in intramitochondrial [Ca2+] ([Ca2+]m) promotes opening of 
the mitochondrial PTP and is associated with increased formation of ROS. 
Eventually a vicious cycle is generated whereby high [Ca2+]m, PTP opening and 
ROS formation hamper mitochondrial function jeopardizing the maintenance of 
cell viability.48, 49 PTP is a voltage-dependent, high-conductance channel located 
in the inner mitochondrial membrane that allows the permeability transition. 
This means that PTP elicits a sudden increase of the inner membrane 
permeability to solutes with molecular weights up to 1500 Daltons. A general 
consensus exists that the PTP is a major factor in determining cardiomyocyte 
death, and that PTP inhibition affords significant cardioprotection against the 
ischemia/reperfusion injury, a concept that has been successfully translated to 
clinical settings.44, 47, 49, 50, 51, 52, 53, 54 
Although ROS can be generated at several intracellular and extracellular sites, in 
cardiac myocytes the major source is represented by mitochondria that are on 
the other hand a prominent target of oxidative stress. A slight generation of ROS 
has been observed in ischemic or hypoxic cardiomyocytes, especially in isolated 
cells. However, a major burst in ROS formation occurs at the onset of reperfusion 
providing a significant contribution to the rapid evolution toward cell death. 
Alterations of respiratory chain induced by ischemia are likely to contribute 
largely to mitochondrial ROS generation during reperfusion. However, it must be 
pointed out that besides respiratory chain complexes, especially I and III, also 
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MAOs, p66Shc, and NOX4 importantly contribute to the oxidative stress. 
Interestingly, pharmacological inhibition or genetic deletion of these ROS-
generating systems results in a significant decrease of reperfusion-induced loss 
of cardiomyocyte viability.11, 22, 23, 53 
 
 
Figure 2. IR phases. From Di Lisa, Mitochondria in Myocardial Ischemia, Encyclopedia of 
Biological Chemistry, 2013.49 
  
4.4.1 Inflammation in IR injury 
 
ROS-dependent expression of pro-inflammatory stimuli and expression of 
adhesion molecules by endothelial cells and leukocytes promotes the infiltration 
and activation of neutrophils, T cells and monocytes.55 ROS also act to enhance 
the inflammatory response to reperfusion via formation of oxidant-dependent 
proinflammatory mediators and upregulation of cytokine and adhesion molecule 
expression.  
A broad spectrum of local and systemic mechanisms is initiated in myocardial 
infarction and contributes to cardiac remodelling. If uncontrolled, it may lead to 
negative changes in the geometry, structure and function of the ventricle and 
thus may have deleterious effects on cardiac function in the long term. 
Myocardial infarction (MI) is a condition of irreversible myocardial necrosis that 
results from a prolonged ischaemic insult. Owing to the limited regenerative 
potential of the myocardium, cardiomyocyte death elicits a reparative response 
that ultimately results in the formation of a scar, leading to focal contractile 
impairment and ventricular remodelling. Damaged cardiomyocytes in the 
infarcted area initiate the reparative response by releasing specific molecules, 
such as damage associated molecular patterns (DAMPs). These are recognized by 
TLRs expressed on leucocytes, parenchymal cells, and also on healthy 
which is observed in the intact heart when reperfusion takes
place after a prolonged ischemia. However, in the intact
heart, irreversible damage is characterized by the loss of cell
membrane integrity, easily demonstrated by thereleaseof intra-
cellular proteins in the coronary effluent (Figure 1). Con-
versely, hypercontracted myocytes often retain the integrity of
sarcolemma, as demonstrated by the retention of small mole-
cules such as intracellularly trapped fluorescent probes. The
difference between single cells and intact hearts is likely
explained by the lack of cell attachments. The same morpho-
logical distortion which determines the hypercontracture in
isolated myocytes could probably cause the rupture of the
sarcolemma in theintact heart by tearing off adjacent myocytes.
Mitochondria in the Transition from Rever ible to
Irreversible Injury
Prolongation of ischemia (i.e., more than 20 min of no-flow
ischemia in perfused hearts) leads myocytes to a point of no
return beyond which even readmission of oxygen fails to res-
cue cell viability.
Myocardial tissue exhibits a peculiar transition from revers-
ible to irreversible damage. In every cell type, the lack of ATP
production and a severe decrease of its content result in a slow
degenerative process which eventuates in the loss of plasma
membrane integrity with release of intracellular components.
Thus, if the initial pathological stimulus (i.e., lack of oxygen) is
not removed, the inhibition or the alteration of mitochondrial
function results in cell death. In addition to this common
mode of cell death, which occurs gradually, the myocardium
exhibits a peculiar transition to irreversible injury, which
occurs suddenly when oxygen supply is re-established after a
prolonged period of ischemia. In this case, the uncontrolled
hypercontracture of myofilaments is associated with a rapid
increase in cell membrane permeability f llowed by the release
of intracellular constituents.
The sudden changes produced by reperfusion on myocar-
dial viability are concomitant with massive accumulation of
calcium within the mitochondrial matrix. This seminal finding
that ighlighted the role of intracellular Ca2þ overload in
myocardial pathology indicates that the rapid transition
toward cell death requires a coupled mitochondrial respira-
tion. In fact, respiratory chain inhibition or uncoupling of
oxidative phosphorylation blun s enzyme releas occurring at
the onset of post-ischemic reperfusion. Therefore, oxidative
phosphorylation not only is essential for cell recovery, but
can also contribute to the processes causing cell necrosis.
Two major questions arise from these seminal findings:
(1) Why ismitochondrial function required to causehypercon-
tracture or tissue injury upon reperfusion? (2) Which are the
causes of mitochondrial dysfunction?
The apparent paradox linking mitochondrial function with
cell death is related to the differ nt ATP requir ments of con-
traction and relaxation at the myofilament level. A suboptimal
mitochondrial function could produce low levels of ATP
which, in the presence of even a modest rise in [Ca2þ ] i, might
be sufficient for the formation of rigor bonds but not for the
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neighbouring cardiomyocytes. Injured cardiomyocytes release DAMPs, such as 
high-mobility group box 1 (HMGB1), DNA fragments, heat shock proteins, and 
matricellular proteins, which instruct surrounding healthy cardiomyocytes to 
produce inflammatory mediators. These mediators, mainly interleukin IL-1β, IL-
6, macrophage chemoattractant protein (MCP)-1, and TNF-α, in turn activate 
versatile signalling networks within surviving cardiomyocytes and trigger 
leucocyte activation and recruitment.56, 57, 58 
 
4.5 Inflammatory response 
 
In the healthy organism, the innate immune system provides the first line of 
defense against external or internal danger signals, by initiating a protective 
inflammatory response. This develops during time through different phases, 
from initiation and full inflammation, to resolution and reestablishment of tissue 
integrity. The first phase of an inflammatory response is aimed at destroying 
pathogens, and is followed by a phase in which dead and dying cells, damaged 
extracellular matrix material, and cellular debris are removed, to end up with a 
recovery phase in which the tissue is repaired and restored to a healthy fully 
functional condition. In fact, if the defense against harmful threats is a priority 
for avoiding tissue damage, maintaining homeostasis, tissue morphology and 
function, is the ultimate goal of a tissue in multicellular organisms. In this 
perspective, inflammation evolved as an adaptive response to tissue malfunction 
or homeostatic imbalance. However, since the inflammatory activities are 
potentially harmful to the host, these need to be tightly controlled to avoid 
excessive tissue damage. 
Pathogen-associated molecular patterns (PAMPs) together with alarmins DAMPs 
are different sets of molecules that alert the organism to intruding pathogens 
(PAMPs) or to an endogenous damage (DAMPs). PAMPs and DAMPs are 
recognized by cells of the innate and acquired immunity system, through toll-like 
receptors (TLRs) or interleukin receptor 1 (IL-1r), which are classical receptors 
leading to inflammatory and immune responses. In addition RAGE is another 
receptor that appears to play a key role in alarmin function.59, 60 
All these receptors activate several signaling pathways. As a result, some cells 
are activated to destroy the pathogen and/or pathogen-infected cells, and an 
immunological response is triggered in order to produce and select specific T cell 
receptors and antibodies that are best suited to recognize the pathogen on a 
future occasion.60 
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4.6 Mono Amine Oxidases (MAOs) 
 
4.6.1 Structural features 
 
Mono Amine Oxidases are flavoenzymes that catalyze the deamination of 
biogenic amines. They are expressed in 2 isoforms, A and B, that display about 
70% of identity. They are encoded by separate genes located on the X 
chromosome (Xp11.23), each comprising 15 exons with identical intron–exon 
organization.111, 112 
Exon 12 codes for the covalent FAD binding site and is the most conserved exon 
between the two isoforms. Both A and B isoform contain the pentapeptide Ser-
Gly-Gly-Cys-Tyr, where the cofactor FAD is covalently bound through a thioether 
linkage to the cysteine residue, namely Cys406 and Cys397 in MAO-A and –B, 
respectively. 
This flavin moiety is the only redox factor necessary for the activity of both 
isoforms. MAO-A and -B are located to the outer mitochondrial membrane. They 
are anchored through a C-terminal helix segment that protrudes from the basal 
face of the structure and is highly hydrophobic, therefore facilitating the 
insertion into the membrane. The covalent binding of the flavin coenzyme of 
MAO-B allowed its identification which was resolved in the early 1970s by 
Singer’s laboratory 113, 114 and subsequent work determined an identical 
structure for the covalent flavin coenzyme of human MAO-A.115 
Both isoforms show the site of covalent FAD binding near the carboxyl terminus 
and the sequence site for the fold (found in most FAD-dependent enzymes) near 
their respective amino terminus.116 Besides the covalent attachment of the FAD 
to the cysteine residues, MAO polypeptide chains undergo also post-translational 
modifications. The best-characterized processes are the removal of the initiator 
methionine in MAO-B (but not in MAO-A) and the acetylation of the N-terminus 
in both molecules (methionine for MAO-A and serine for MAO-B). In addition to 
the acetylation of the N-terminus, human, rat and mouse MAO-A and -B from 
several tissues have been shown to contain several acetylated lysine residues, 
although whether and how this modification affects MAO function remains 
unclear. Eventually, there are also several serine residues in both MAO-A and -B 
that can be phosphorylated. Among these, Ser209 inside a putative p38 
consensus motif has been widely studied as a possible phosphorylation site.117, 
118 In fact, at present no definitive evidence exists for phosphorylated forms of 
MAO in biological systems and its putative influence on catalytic activity. 
Furthermore other studies documented that MAO catalytic activity does not 
always correlate to its level of expression, suggesting that the protein levels are 
not a key regulator of the enzyme activity.117, 118, 171 MAO-B crystallizes as a 
dimer, with each monomer presenting a C-terminal membrane bound domain, a 
FAD binding domain and a substrate binding domain.120, 120 In contrast to human 
MAO-B, human MAO-A crystallizes as a monomer.122 It has only single substrate 
binding cavities with protein loops at the entrances of either cavity. The single 
cavity in MAO-A displays a rounder shape and is larger in volume than the 
substrate cavity in MAO-B. Analysis of residue side chains in either active site 
shows the substrate to have less freedom for rotation in the MAO-B site than in 
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MAO-A. The structural basis for this difference can be partially attributed to the 
conformational differences of the 200-215 residue segment that constitutes the 
“cavity shaping loop” in both isoforms. This loop is in a more extended 
conformation in MAO-A and in a more compact conformation in MAO-B. 
The MAO-A and MAO-B genes are closely linked and organized in opposite 
directions, tail to tail 24kb apart. However, they have different promoter 
organizations (fig. 3).  
 
 
Figure 3. Schematic representation of MAO-A and –B genes and their core promoters. From 
Shih et al, 2004.123 
 
The MAO-A proximal promoter consists of three binding sites for the 
transcription factor Sp1 in reverse orientations and it lacks a TATA box. This 
promoter is activated by Sp1 and repressed by a R1 (RAM2/CDCA71) repressor 
(fig. 3). Three glucocorticoid/androgen response elements were also found 
within the first 2kb of the human MAO-A promoter. The MAO-B proximal 
promoter contains a TATA box and two clusters of Sp1 binding sites, separated 
by a CACC box. It was also shown that the more distal of the MAO-B Sp1 clusters 
can also bind to Egr1 (Early growth response protein 1) transcription factor.124, 
123, 125, 126 
 
4.6.2 Tissue distribution 
 
MAO has been localized in rodent, cat, primate, and human. It is present in most 
of the mammalian tissues but it differs depending on tissue nature and isoform 
expression.112 
The distribution of MAO in various tissues of different species has been 
investigated by use of specific inhibitors, immunohistochemistry, enzyme 
autoradiography and in situ hybridization.127, 128, 129 Brain has been intensively 
studied. In this organ MAO-A has been prevalently found in noradrenergic and 
dopaminergic neurons. Conversely, MAO-B has been detected in cell bodies of 
serotoninergic neurons, in histaminergic neurons and in glial cells. The 
distribution of MAO in the periphery varies within the same organism. MAO-A 
has been found in placenta, fibroblasts, liver, intestine and thyroid gland,130, 131 
while platelets, liver, pancreatic islets and kidney contain mainly MAO-B.119, 132, 
133, 134, 135, 136, 137, 138, 139 
The presence of MAO in most tissues appears to reflect a functional need. 
However, in some regions of the brain MAO and its substrates are not found in 
the same neurons. For example, MAO-A preferentially metabolizes 5-HT but it is 
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that their expression might be regulated by the activation of receptors coupled to 
adenylate cyclase
32, 33
.
2.1.5 Pathologies related to MAO
The roles of MAO in terminating the actions of n urotr nsmitt rs/dietary 
amines in central and peripheral nervous system and in the extraneuronal tissue 
have been extensively studied. In contrast, less attention has been given to the 
products of their activity. The monoamine catabolism byproducts are aldehydes, 
ammonia and H2O2, a reactive oxygen species that could be toxic per se at high 
concentrations34, 35 or it could generate hydroxyl radical when in the presence of 
Fe
2+
. MAO are involved in numerous pathologies, in particular in neuronal and 
psychiatric disorders. MAO-B appears to be involved in the loss of dopaminergic 
neurons that occurs in Parkinson’s disease, most likely due to the increased 
dopamine catabolism, resulting in elevated production of reactive oxygen species 
responsible for the oxidative damage at the level of nigrostriatal neurons. Indeed, 
MAO-B inhibition has been proven to afford neuroprotection
36
. An increase in 
MAO-B activity in brain is also associated with diseases such as Alzheimer’s or 
Huntington’s disease. Depression, panic attacks and personality disorders are also 
associated ith changes in dopaminergic, noradrenergic and serotoninergic 
neurotransmission, which are regulated by both isoforms of MAO.  
Figure . Schematic representation of MAO-A and –B genes and 
their core promoters. From Shih et al, 2004. 
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not found in serotonergic neurons, and MAO-B preferentially metabolizes 
phenylethylamine but it is present in serotonergic neurons and glial cells. The 
role of MAO, as previously discussed, in these regions may be to protect neurons 
from stimulation by oxidizing amines.140, 141, 143 
In humans and rodents, MAO-A is present more than MAO-B in most tissues. 
MAO-A expression levels still remain quite the same along organism lifetime, 
whereas MAO-B activity increases several-fold with aging.144, 145, 134, 146 Human 
cardiomyocytes contain both isoenzymes, even if MAO-A is the predominant 
isoform.147 Rat cardiomyocytes prevalently contain isoform A while murine 
cardiomyocytes isoform B.119, 111 
 
4.6.3 Biochemical role 
 
The main biochemical role of MAO is the degradation of endogenous monoamine 
neurotransmitters and dietary amines by the following reaction of deamination 
(fig. 4): 
 
Figure 4. MAO enzymatic reaction. 
 
This reaction occurs in two steps, ultimately resulting in the formation of the 
aldehyde from the corresponding amine, ammonia and H2O2. The aldehyde 
intermediate is rapidly metabolized to the corresponding acid by the action of 
aldehyde dehydrogenases (ALDH). By kinetic studies it has been demonstrated 
that the binding of the amine group to the enzyme precedes the binding of 
oxygen. In a first phase, the reduction of the cofactor FAD yields an aldehyde 
intermediate and ammonia, while in a second phase the oxidized form of the 
prosthetic group is restored with the concomitant production of H2O2 (fig. 5). 
 
Figure 5. MAO reaction. 
 
Aldehyde intermediates are toxic for the biological systems and a decrease in 
ALDH activity, also due to increased oxidative stress, might further contribute to 
the exacerbation of damage. H2O2 is a ROS that could be toxic per se under stress 
or pathological conditions, or it could generate hydroxyl radical in the presence 
of Fe2+.119 Together these products represent a peculiar aspect of MAO profile. 
However much less attention has been dedicated to them in comparison to the 
numerous studies on MAO activity in terminating the actions of 
neurotransmitters/dietary amines in central and peripheral nervous system and 
in the extraneuronal tissue.  
MAO is the only known mitochondrial ROS source that can be inhibited 
pharmacologically without interfering with energy metabolism. Major 
advantages of investigating the role of MAO in oxidative stress are given by a 
defined molecular structure, specific substrates, and clinically available 
inhibitors.148 MAO-A deaminates preferentially norepinephrine (NE) 
epinephrine and serotonin (5-HT) and it is inhibited by clorgyline. MAO-B has 
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de) come coenzima e agiscono catalizzando la deaminazione ossidat iva di alcuni neuro-
t rasmet t itori endogeni, come noradrenalina, dopamina, serotonina e di ammine esogene, 
come la t iramina (Pizzinat  et al., 1999). 
Le MAO sono in grado di ossidare sia le ammine prima-
rie che quelle secondarie, mentre risentono dell’effetto di am-
mine aromat iche con residuo di et ino (come pargilina e clorgi-
lina), che le inibiscono in modo completo ed irreversibile.  
Si riconoscono due moment i fondamentali, nel primo dei quali la riduzione del 
FAD+  comporta la produzione di un intermedio aldeidico  d  ammoniaca, nel secondo 
si ha il riprist ino della forma ossidata del FADH2 per azione dell’ossigeno molecolare, 
con conseguente produzione di idrogeno perossido (T ipton et al., 2004), secondo le rea-
zioni A  e B  di seguito riportate: 
A .  R–CH
2
NH2 +  FAD
+
 → R–CHO +  NH3 +  FADH2  
B. O2 +  H2O +  FADH2 → H2O2 +  FAD
+
  
Nel caso delle ammine primarie si rit iene che la prima reazione parziale proceda 
at t raverso la formazi ne di un intermedio amminico, che viene in seguito idrolizzat  
dall’H2O nel prodot to nale: 
C.  R–CH
2
NH2  
–2H+
 R–CH=NH 
+ H2O
 R–CHO +  NH3  
Successivamente, l’intermedio aldeidico viene rapidamente metabolizzato, di solito 
per ossidazione al corrispondente acido at t raverso l’azione dell’aldeide deidrogenasi; può 
alt resì venir  ridot to ad alcool o glicole per mezz  dell’aldeide dei ro enasi. Va sot toli-
neato che la quant ità di H2O2 generata dalle MAO mitocondriali è di molto superiore 
alla quant ità prodot t dalla catena respiratoria; è evidente quindi come le MAO pos-
seggano un considerevole potenziale tossico e siano coinvolte nell’induzione o nello svi-
luppo di numerose patologie quali il danno da riperfusione post -ischemica, le malat t ie 
neurodegenerat ive, l’invecchiamento, gli e et t i tossici di determinat i farmaci. 
Figura 1.2: Pargilina. 
Inibitore MAO non selettivo. 
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major affinity for phenylethylamine, Nτ-methylhistamine (NMH) and 
benzylamine, and it is inhibited by selegiline, also known as L-deprenyl, and 
safinamide. Both isoforms catalyze the deamination of dopamine, tyramine, 
octopamine and tryptamine and are inhibited by pargyline.112, 126, 149, 150 
 
4.6.3.1 MAO role in nervous system 
In the central and peripheral nervous system, intraneuronal MAO-A and –B 
protect neurons from exogenous amines, terminate the actions of amine 
neurotransmitters and regulate the contents of intracellular amine stores. In the 
human brain, MAO-A and -B are both present in catecholaminergic cells even if 
the isoform A is more expressed, while MAO-B is preferentially expressed in 
serotonergic neurons and astrocytes.112, 126 Given the low level of MAO-A in 
serotonergic neurons it has been speculated that 5-HT removal could be due to 
the surrounding glial cells.112 
Extraneuronal MAO functions also in the inactivation of amines taken up by glial 
cells and astrocytes.112 
 
4.6.3.2 MAO role in peripheral tissues 
MAO in peripheral tissues, such as intestine, liver, lungs and placenta, protects 
the body removing amines from the blood or by preventing their entry into the 
circulation.112 MAO-B in the microvessels of the blood–brain barrier presumably 
has a similar protective function, acting as a metabolic barrier.112 
 
4.6.3.3 MAO role in heart 
In the heart, MAO represents an important source of ROS, and it has been 
reported that it can promote and worsen oxidative stress conditions upon 
cardiac injuries.29, 151 MAO-A is involved in the receptor-independent apoptotic 
effects of 5-HT in isolated cardiomyocytes, in post ischemic myocardial injury152, 
153 and in 5-HT-induced myocyte hypertrophy in vitro.153 Regarding vasculature, 
it has been shown that MAO-A induces mitogenic signaling in smooth muscle 
cells by H2O2 leading to the activation of the metalloproteinase MMP-2, which 
likely contributes to vascular wall remodelling.154 
 
4.6.4 MAO related pathologies 
 
4.6.4.1 Loss of function 
Deletion of MAO-A and MAO-B has proven their important roles in both 
metabolism of neurotransmitter and behavior. MAO-A knockout mice displayed 
elevated levels of brain 5-HT, NE and, to a lesser extent, dopamine, whereas only 
phenylethylamine is increased in MAO-B knockout mice. Both MAO-A and –B 
knockout mice show increased reactivity to stress, similar to that observed after 
administration of non-selective MAO inhibitors.155 
Combined loss of MAO-A and MAO-B activity has been described in some 
patients with an X chromosome deletion that includes not only the Norrie 
disease but also the MAO-A and MAO-B genes. Furthermore, despite loss of MAO-
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A and MAO-B activity, the organism survival indicates that MAO is not 
essential.156 
In addition to blindness, hearing loss, and variable mental retardation that 
characterize Norrie disease, patients with the additional deletion of both MAO 
genes show profound mental retardation, autistic-like behaviour, atonic seizures, 
altered peripheral autonomic function, and profound alterations in biogenic 
amine metabolism. More recently, selective loss of MAO-A activity due to a point 
mutation in exon 8 of the MAO-A gene was described in Dutch kindred.156, 157 
In this disease, selective MAO-A deficiency was associated with a clinical 
phenotype characterized by borderline mental retardation and impaired impulse 
control, including a propensity towards stress-induced aggression. Furthermore, 
these observations have proven that MAO-A activity is important during 
development even if not for the survival of the organism. 
Selective deficiency of MAO-B does not lead to a specific clinical phenotype and, 
in particular, is not associated with clinically apparent disturbances in behaviour 
such as those observed in deficiencies of MAO-A. This indicates that MAO-A is 
considerably more important than MAO-B for metabolism of most biogenic 
amines in the nervous system. These functional differences in the two 
isoenzymes may help in understanding the basis for therapeutic interventions 
involving specific inhibition of one or the other isoform.155 
 
4.6.4.2 Gain of function 
4.6.4.2.1 Neurological diseases 
In addition, MAO products, H2O2, ammonia and aldehydes, might have important 
metabolic and signaling functions in both physiological and pathological 
conditions, as already studied in the brain. For example, 5-HT and NE 
deamination leads to H2O2 and aldehydes production that might be involved in 
the regulation of sleep. However, H2O2 and aldehydes at higher concentrations 
are cytotoxic.158, 159, 160 The aldehyde derived from dopamine, which does not 
appear to accumulate in the healthy brain, is cytotoxic in condition of 
neurodegenerative pathology. This might be important in Parkinson’s disease, in 
which the levels of ALDH in the substantia nigra are greatly reduced.112 In 
addition, MAO-dependent H2O2 overproduction contributes to the degeneration 
of nigral cells in Parkinson’s disease. In Parkinson’s disease MAO inhibition or 
iron chelation achieves the same neuroprotective effect, strongly suggesting that 
a reduction of local oxidative stress is a major component of this 
neuropathology.161 
Other studies have reported that MAO-B isoform is increased in the brains of 
patients with Parkinson’s disease. Thus MAO-B inhibitors such as l-Deprenyl and 
safinamide were investigated as adjuvants to l-DOPA, the aminoacidic precursor 
of NE and dopamine already used in the treatment of Parkinson. Those studies 
reported l-Deprenyl and Safinamide are efficient both as adjuvants to the 
treatment with l-DOPA. Furthermore, l-Deprenyyl is effective also as 
monotherapy.162 
Neurodegenerative diseases, such as Huntington’s disease and amyotrophic 
lateral sclerosis (ALS), share many of the pathological features of Parkinson’s 
disease and Alzheimer’s disease, such as oxidative stress, iron accumulation, 
excitotoxicity, inflammatory processes and the misfolding of toxic proteins that 
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cannot be degraded after ubiquitination. Regarding Alzheimer’s disease, lot of 
studies are focused on the design of new MAO inhibitors, starting from the 
structure of selegiline, propargylamine and coumarin derivatives.163, 164, 165, 166 At 
the moment, only rasagiline, a specific MAO-B inhibitor, has been reported to be 
effective in mouse models of ALS, indicating the need of further studies to assess 
MAO inhibitor as eventual and successful drugs in these conditions.112 
 
4.6.4.2.2 Tumors 
Some papers also reported a link between MAO and tumor growth. It has been 
published that MAO-A is significantly downregulated in hepatocellular 
carcinoma (HCC) by epigenetic alteration and that its expression is closely 
associated with the key events of tumor metastasis.167 Conversely, MAO-A 
expression is increased in human glioma tissue specimens and cells, wherein 
clorgyline, MAO-A inhibitor, is effective in reducing tumor growth and cell 
survival.168 MAO-A is also increased in Prostate Cancer cells and it promotes 
HIF1α/VEGF-A/FOXO1/ TWIST1 pathway that enhances tumor growth.169 
 
4.6.4.2.3 Muscular diseases 
MAO-A-mediated oxidative stress can also lead to cell damage, representing a 
novel pathogenetic mechanism for glucocorticoid-induced myopathy and a 
potential target for therapeutic intervention. MAO-A expressed in response to 
glucocorticoid administration plays an important role in glucocorticoid-induced 
toxicity in skeletal myocytes by producing H2O2.170 MAO-dependent oxidative 
stress is also involved in myofiber damage. Indeed, it has been demonstrated 
that MAO inhibition is able to reduce the occurrence of myofibrillar protein 
oxidation and myofiber defects in two murine models of muscular dystrophies 
(MDs). In addition, besides reducing biochemical and histological alterations, 
MAO inhibition ameliorates contractile performance highlighting the relevance 
of mitochondrial ROS formation in MDs.171 
Pargyline treatment was shown to significantly reduce both ROS accumulation 
and mitochondrial dysfunction, and to normalize the increased incidence of 
apoptosis in myoblasts from patients affected by collagen VI myopathies. Those 
observations indicated that MAO-dependent oxidative stress is causally related 
to mitochondrial dysfunction and cell death also in human myoblasts.172 
 
4.6.4.2.4 Heart diseases 
MAO activity affects also cardiac biology and function with different possible 
mechanisms.119, 173 MAO-dependent ROS formation contributes to the apoptotic 
cascades induced by IR.29 Indeed MAO substrate 5-HT-derived ROS have been 
shown to promote apoptosis in IR-associated events, such as myocardial 
dysfunction. The production of MAO proapoptotic ROS is linked to ceramide 
increase but also to the fall in the intracellular antiapoptotic S1P content caused 
by a decline of Sphingosine Kinase 1 (SphK1) protein and activity. SphK1 
overexpression markedly inhibits ROS-mediated, serotonin-induced 
cardiomyoblast apoptosis. Enforced SphK1 expression reduced ceramide 
elevation (triggered by 5-HT) by driving ceramide metabolism toward the 
synthesis of S1P. MAO mediates SphK1 activity and changes the ceramide/S1P 
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sphingolipid balance promoting cardiomyocyte apoptosis.152, 174 
Blockade of endogenous MAO activity reduces also the vascular formation of 
H2O2 and partially restores normal endothelium-dependent relaxation in vessels 
pre-exposed to Ang II or LPS.175 
A study by Villeneuve and colleagues showed that cardiac-specific 
overexpression of MAO-A was accompanied by ultrastructural defects of cardiac 
mitochondria, ATP depletion and ultimately led to cardiomyocyte necrosis and 
heart failure.176 Our laboratory demonstrated also that enhanced MAO-A activity 
coupled with increased intramyocardial NE availability results in augmented 
ROS generation. This pairing contributes to maladaptive remodeling and left 
ventricular dysfunction in hearts subjected to chronic stress.177 Furthermore 
MAO inhibitors improve cardiac function in patients with heart failure.119 
 
4.7 Macrophages 
 
 
 
Figure 6. Cell recruitment upon inflammation. From Frangogiannis, 2014.57 
 
During the initial phases of an inflammatory reaction, there is the recruitment of 
leukocytes (fig. 6). These cells are represented by different cytotypes that 
contribute to the inflammatory response, such as monocytes (fig. 6), dendritic 
cells, macrophages, lymphocytes. 
Circulating monocytes can be recruited by tissue resident macrophages, 
lymphocites alongside with other tissue cells in the site of inflammation where 
they differentiate depending on the environmental stimuli. Monocytes are plastic 
cells able to differentiate in two main subtypes: dendritic cells and macrophages. 
Dendritic cells are also defined antigen-presenting cells. Their task is to process 
antigen molecules to present them on their surface to T cells. Macrophages (MΦ) 
are phagocytic cells that are classified in many groups. 61, 62, 63, 64, 65, 66, 67 We will 
focus on the two main representing classes: M1 and M2. M1 MΦ (or classically 
activated macrophages, CAMs) are pro-inflammatory and have potent 
microbicidal and tumoricidal activity, whereas the M2 MΦ (or alternatively 
activated macrophages, AAMs) are involved in tumor progression and tissue 
remodeling, including fibrosis.67 
Monocytes 
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4.7.1 Macrophage differentiation 
 
 4.7.1.1 Resident MΦ 
The so-called resident MΦ can be heterogeneous cells and they derived from 
hematopoietic precursors or from primitive cells of the yolk sac. They can either 
persist in an organ by local proliferation or depend on monocyte recruitment for 
repopulation. Once they reached the tissue, macrophages appear to retain their 
plasticity and not only change their own physiology, but also alter the physiology 
of cells adjacent to them.68, 67 
 
4.7.1.2 Monocyte derived MΦ 
Monocytes differentiate in macrophages responding to different stimuli, and 
these are the classically used: granulocyte-macrophage colony stimulating factor 
(GM-CSF) and macrophage colony stimulating factor (M-CSF, also known as CSF-
1). GM-CSF and M-CSF drive the monocyte/macrophage development, 
differentiation, and proliferation.69, 70 
GM-CSF is a glycoprotein that acts through its specific receptor, called Csf2rα,71, 
72 to promote M1 polarization (fig. 7). It activates a signaling pathway 
constituted by IFNγ-mediated Janus kinase–signal transducer and activator of 
transcription (JAK–STAT) that induces IFN regulatory factor (IRF5) 
transcription. High expression of IRF5 is characteristic of M1 macrophages, in 
which it directly activates transcription of the genes encoding interleukin 12 and 
IL-23 and represses the gene encoding IL-10.70, 73, 74, 75 
The biological effects of M-CSF molecule are mediated by its unique receptor (M-
CSFR), a member of the tyrosine kinase receptor family encoded by the c-fms 
proto-oncogene, which is prominently expressed in cells of the monocyte/ 
macrophage lineage.76, 77 Binding of M-CSF to the extracellular domain of the M-
CSFR leads to receptor autophosphorylation on specific tyrosine residues that 
serve as anchoring sites for signaling molecules (fig. 7). Therefore, activated M-
CSFR plays a pivotal role in the assembly of the specific multimeric complexes 
that will physically organize downstream signaling pathways, including the PI 3-
kinase/Akt pathway and the Ras/Raf/MEK/MAPK pathway to eventually 
promote M2 differentiation.78 79, 80, 81 
 
4.7.2 Macrophage polarization 
 
The second step in macrophage development is linked with their polarization. 
Macrophage polarization occurs through different activation programs by which 
macrophages carry out their defensive functions (fig. 7). In this way, 
macrophages become able to respond with appropriate functions in distinct 
contexts. Essentially, macrophages can still modify their metabolic functions 
from a killing/inhibitory capacity (M1 MΦ), to a heal/growth promoting setting 
(M2 MΦ).69 
M1 activation commonly requires priming with IFN-γ, the canonical cytokine 
generated by Th1 cells, lipopolysaccharide (LPS) (used in this work), a plasma 
 27 
membrane component of Gram-negative bacteria, and activation of the 
downstream transcription factors, such as STAT1, nuclear factor-kappa light 
chain-enhancer of activated-B cells (NF-κB), and IRF-5, as already reported 
during M1 differentiation process. These M1 macrophages express inflammatory 
genes, including tumor necrosis factor α (TNF-α), IL-1β, and IL-6.  
M2 macrophages are activated by Th2 cytokines, IL-4 and/or IL-13.  
M2 polarized MΦ produce IL-10, IL-1 receptor antagonist (IL-1ra), and 
transforming growth factor-β (TGF-β), that attenuate inflammation and promote 
extracellular tissue remodeling. Transcription factors involved in M2 
polarization, as during differentiation, include STAT3, STAT6 and IRF-4, and 
peroxisome proliferator-activated receptor (PPAR)-γ.70 
M1 and M2 MΦ have distinct features in terms of chemokine production profiles, 
and iron and glucose metabolism. M1 show an elevated activity in the pentose 
phosphate pathway, and an elevation in certain Krebs cycle intermediates, 
including succinate and citrate. M1 macrophages also have increased synthesis 
of fatty acids and all these metabolites can act as signals to alter M1 cell function. 
In contrast, metabolism in M2 macrophages comprises high levels of fatty acid 
oxidation and oxidative phosphorylation.69, 70, 81 
 
 
Figure 7. Main signal transduction pathways to M1 and M2 MΦ 
differentiation/polarization. From Lawrence and Natoli, 2011.70 
 
4.7.3 Mitochondria in phagocytic cells 
 
Therefore, mitochondria in phagocytic cells can no longer be viewed solely as the 
energy machinery but as a vital source of dynamic signals that respond to the 
surrounding environment. LPS activation stimulates the production of citrate, 
succinate and ROS, all of which act in a pro-inflammatory manner to fight 
infection. On the other-hand, IL-4 coerces macrophages towards high levels of 
fatty acid oxidation and oxidative phosphorylation, both of which are essential 
γ γ γ
γ
γ
γ
γ
 Signal transduction pathways to M1 and M2 macrophage polarization. 
implicated in M1 and M2 macrophage polarization are indicated. An initial stimulus leads to the activation of 
sequence-specific transcription factors that eventually mediate the changes in the transcriptional output.  
The main genes that are characteristic of either the M1 or the M2 polarized state are also shown. Arg1  
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γ, interferon-γ; IL, interleukin;  
Mrc1, macrophage mannose  
κB, nuclear factor-κB; Nos2
γ, peroxisome proliferator-activated receptor-γ; Retnla, resistin-like-α; 
and then CX
3
CR1hiLY6C– macrophages from the 
blood87. It is clear that these two interpretations are 
not mutually exclusive: early recruited macrophages 
might u dergo a reprogramming to CX
3
CR1hiLY6C– 
M2-type cells similar to those obtained in vitro following 
prolonged exposure to LPS, but the changing micro-
environment in the damaged tissue might at later stages 
promote the preferential recruitment of CX
3
CR1hiLY6C– 
macrophages from the blood. In any case, addressing 
the mechanistic bases of these complex population 
dynamics in vivo will be extremely challenging.
Conclusions and future direct ions
The notion that macrophages phenotypically adapt to 
the environmental milieu, and that this is associated 
with radical changes in their transcriptional output, is 
now strongly rooted in the field and supported by a 
large amount of data, albeit scattered and not always 
systematic. At the same time, the molecular determi-
nants that precisely control macrophage plasticity are 
to a large extent unknown. A major area of research in 
the future, now made possible by advances in genomic 
technologies, will be the pairwise definition of the tran-
scriptomes and chromatin landscapes (epigenomes) of 
macrophages obtained from tissues in both normal 
and diseased conditions. As macrophages continuously 
sample the environment and quickly react to it, a major 
challenge will be the optimization of quick and mild 
purification procedures that will minimize techni-
cal artefacts. Informati n generated t rough these 
approaches will be used to infer pathways and tran-
scription factors that are specifically dedicated to the 
activation of specialized gene expression programmes 
with distinct functional outcomes (FIG. 5). The direct 
therapeutic implications are still difficult to envisage 
but, in principle, detailed knowledge of the mechanisms 
that control specific macrophage phenotypes might be 
used to reprogram their function for therapeutic ben-
efit. For example, reactivating pro-inflammatory genes 
in TAMs might help to promote tumour rejection. 
Moreover, reversing the anergic state of LPS-tolerized 
macrophages in patients recovering from septic shock 
might help to prevent secondary infections, which still 
represent a major cause of morbidity and mortality in 
these patients12. In addition to the pro-inflammatory 
functions of macrophages, the anti-inflammatory 
properties of M2-like macrophages and their homeo-
static functions in wound healing and tissue repair 
might be harnessed to prevent the tissue injury caused 
by chronic inflammation. Nevertheless, targeting tran-
scription factors for therapeutic aims is still a largely 
unexplored and definitely challenging area.
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for longer-term survival of macrophages required for their roles in wound repair 
and resolution of infection. 
We can therefore directly map the mitochondrial phenotype of macrophages to 
their specific effector functions, which has exciting therapeutic prospects. It is 
possible that manipulating the metabolism of macrophages could boost immune 
responses, or indeed dampen inflammatory responses in the case of auto- 
immunity.70, 81 
Furthermore, it has been demonstrated the involvement of mitochondria in LPS-
induced ROS signalling; (i) to propose the mitochondrial protein UCP2 as a key 
regulator of this process; and (ii) to provide mechanistic evidence to explain the 
immune phenotypes of UCP2−/− and UCP2+/+ macrophages.83 
 
4.7.4 ROS regulate macrophages 
 
The role of oxidative stress in macrophage metabolism is controversial and still 
under debate.  
Several roles of mitochondrial ROS production have been identified in M1 
macrophages. Firstly, ROS is directly bactericidal. LPS signaling induces tumor 
necrosis factor receptor-associated factor 6 (TRAF6) recruitment to 
evolutionarily conserved signaling intermediate in Toll pathways (ECSIT) in the 
outer mitochondrial membrane, where it interacts directly with complex I of the 
respiratory chain, promoting its assembly and subsequent ROS production.84 The 
bactericidal ROS enters phagosomes which contain the engulfed bacteria and 
promotes the clearance of infection. Second, ROS can influence the production of 
pro-inflammatory cytokines, including IL-6 and TNF-α.85 ROS prevent the 
dephosphorylation of mitogen activated protein kinases (MAPKs) such as c-Jun 
N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) and p38 
MAPK phosphorylation in response to LPS, which may contribute to enhanced 
cytokine production. Treatment with MitoQ, the specific mitochondrial ROS 
scavenger, also significantly reduced LPS-induced IL-6, TNF-α and IL-10 in 
human PBMCs; this may be a result of decreased MAPK activity. 
Thirdly, mitochondrial ROS has been shown both to activate and prime the 
nucleotide-binding domain and LRR-containing NLR (NLRP3) inflammasome, 
which is a protein complex required for the production of mature IL-1β.86, 87, 88 
Also M2 macrophage differentiation and polarization are driven by ROS. Indeed, 
M-CSF induced production of ROS per se in monocyte differentiation to M2 MΦ, 
as it is required for a physiologic response, such as cell proliferation. It has been 
demonstrated that oxidative inactivation of the redox-sensitive Src homology 
region 2 domain-containing phosphatase 1 (SHP1) specifically might promote 
the PI3K/Akt signaling pathway specific for M2 differentiation. Furthermore, the 
exogenous addition of both H2O2 and M-CSF leads to phosphorylation of Akt in 
addition to MAPKs, including ERK, p38, and JNK, therefore simulating the M2 
differentiating pathway.89 On the other hand, the exacerbation of the oxidative 
stress conditions due to elevated O2•− levels, lead to increased phosphorylation of 
stress-responsive MAPKs, p38, and JNK-1, inciting monocyte activation.90, 90 
It has been demonstrated that the antioxidant BHA blocks IL-4/ IL-10-triggered 
polarization to human and murine M2 MΦ, but did not affect LPS/IFNγ-induced 
polarization to M1 MΦ. These data demonstrate that elimination of ROS during 
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MΦ differentiation only blocked the differentiation to M2, but not to M1 MΦ.92 
Other studies reported various effects of different antioxidants during MΦ 
polarization. Catalase antioxidant activity was ineffective on human 
macrophages, while diphenyleneiodonium (DPI) or N-acetylctsteine has 
demonstrated the capacity to diminish the IL-10 and IL-12 production of the M2 
subsets, although it showed no effect on IL-6 production.93, 94 
Furthermore, ROS are directly requested to modulate autophagy. ROS regulates 
autophagic signaling transduction pathways that induce autophagy such as 
mTOR and MAPK and these evidences were clear by the use of anti-oxidant.94 
Another report showed that most monocytes do not survive when autophagy is 
blocked during differentiation, especially when blocked in its early stages, 
supporting the pivotal role for ROS in macrophage differentiation.95 
 
4.7.5 Macrophages in cardiac injury 
 
It is well known that cardiac injury leads to an inflammatory response, as 
previously described also in paragraph 4.4.2. After myocardial injury, the 
number of macrophages increases, which is important for the progression and 
resolution of tissue injury.68 Initial work suggested that the early phase after 
infarction recruits inflammatory M1 MΦ 96, 98, 99, that, by exercising inflammatory 
functions, are potentially harmful in this early phase, as they promote 
myocardial damage.100 On the other hand, M2 MΦ could promote angiogenesis, 
extracellular matrix synthesis and myocardial healing through secretion of anti-
inflammatory cytokines and growth factors, like VEGF and TGF-β.96, 98, 101 
 
4.7.6 MAO in macrophages 
 
To date the literature related to MAO in macrophages has focused the attention 
only on its cellular expression and on its function of immune transmitter 
removal, such as 5-HT. 5-HT is involved in interactions between the central 
nervous and immune systems through 5-HT1A receptor. These include T cell and 
natural killer cell activation, delayed-type hypersensitivity responses, 
production of chemotactic factors, and natural immunity delivered by 
macrophages.103, 104, 105 
In human peripheral blood monocytes, it has been reported that IL-4 and IL-13 
up-regulate expression of a variety of gene products. Among those genes MAO-A 
presents a 55-fold increase.106, 107 The up-regulation of MAO-A is likely to 
proceed via 15-lipoxygenase (15-LOX1)-dependent and -independent pathways 
as already published. 15-LOX1 is a pro-oxidative enzyme involved in the 
production and metabolism of fatty acid hydroperoxide. U937 cells transfected 
with 15-LOX1 or incubated with primary 15-LOX1 products (hydroperoxy fatty 
acids) or H2O2 showed MAO-A increased expression levels, whereas the 
corresponding hydroxy fatty acids on the same cytotype were ineffective.108 
According to these findings, other papers indicate that Janus Kinases (Jaks), -non 
receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-
STAT pathway-, which are commonly required for LOX induction, are involved 
also in MAO expression. Indeed it has been demonstrated that IL-4 and IL-13-
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activated monocytes induce MAO-A expression through Jak1 and Jak2 upstream 
regulation, respectively.109 
Interestingly tyramine and benzylamine, MAO substrates, elicited a dose-
dependent decrease of LPS/INF-γ-induced nitric oxide synthase (NOS2) 
expression in rat peritoneal macrophages. Pargyline, a MAO specific inhibitor 
antagonized the negative effect of these substrates on NOS2 expression. These 
data demonstrated that MAO-generated H2O2 is an important inhibitor of 
inducible NOS2 expression. Although NOS2 generation of NO is differently 
regulated in murine and human macrophages, it has been speculated that the 
expression of MAO-A in M2 macrophages may stabilize the M2 anti-
inflammatory phenotype in part by preventing the expression of NOS2 and 
generation of NO.110, 105 
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5. Materials and methods 
 
5.1 Cell cultures 
 
5.1.1 Neonatal Rat Ventricular Myocytes (NRVMs) 
 
Littermate Wistar rats, provided by the Department of Biomedical Science in the 
University of Padova, were sacrificed by cervical dislocation. Neonatal rat 
ventricular myocytes (NRVMs) were isolated from P1-3 pups. Hearts were 
collected, washed and excised into pieces and then incubated o.n. at 4°C in 
Hank’s Balanced Solution (HBSS – Sigma) containing 2.5% Trypsin 10X (Thermo 
Fisher Scientific). The day after heart fragments were washed and further 
dissociated with a solution of HBSS and type II collagenase (Thermo Fisher 
Scientific) for 5 times, under continuous stirring. Cell suspension was filtered 
with a 40μm strainer and pelleted. After that cells were plated for 90’. After this 
incubation, only fibroblasts are attached to the flask, while myocytes remain in 
the supernatant. Then cell suspension was counted and plated over plates or 
coverslips previously coated with a solution of 0.1% of porcine gelatin (Sigma).  
Cells were grown in modified essential medium (MEM, Thermo Fisher Scientific) 
supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific), 10 
units/ml penicillin, 100μg/ml streptomycin (Thermo Fisher Scientific), 5-bromo-
2’-deoxyuridine (BRDU, Sigma), 0.1% Non essential aminoacids (NEAA, Gibco-
Thermo Fisher Scientific) and 1X Insulin Transferrin Selenium (ITS, Thermo 
Fisher Scientific). Cells were plated at a concentration of 5x105 cells/ml, 
resulting in 80-90% confluence, and are cultured for 24h in a 5% CO2 incubator 
at 37°C prior to the experiments. 
 
5.1.2 Human Macrophages (MΦ) 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of 
healthy donor (hospital center, Padova) and isolated using a Ficoll (Thermo 
Fisher Scientific) and Percoll (GE Healthcare) density gradient (Fluks, 1981; 
Almeida et al. 2000). Blood was centrifuged to separate cell suspension from 
serum and then washed with PBS 1X (Thermo Fisher Scientific). After that linfo-
monocytes were isolated stratifying the suspension over an equal volume of 
Ficoll and centrifuged 2000 rpm 30’ at room temperature without accelerator 
and decelerator. A second centrifuge was required to purify monocytes from 
lymphocytes taking advantage of a second gradient due to Percoll. At the end cell 
suspension was plated for 1h into 24-well culture plates at a density of 2x106 
cells/well in RPMI without serum to allow monocyte adhesion and then washed 
3 times with Roswell Park Memorial Institute 1640 Medium I to eliminate 
residual lymphocytes (RPMI - Thermo Fisher Scientific). 
Subsequently RPMI containing 20% FBS, 10ng/ml macrophage colony 
stimulating factor (M-CSF, Miltenyi), or 10ng/ml granulocyte macrophage colony 
stimulating factor (GM-CSF, Peprotech) was added to monocytes to induce 
differentiation to macrophages (Thermo Fisher Scientific), After 5 days of 
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incubation at 37°C, 5% CO2 half of the medium was replaced with a fresh one, 
and after 7 days of macrophage differentiation, cells were treated for different 
time periods (1-2-3-24h) to polarize them as described at 5.2. 
 
5.1.3 RAW 264.7 murine cell line 
 
Macrophage RAW 264.7 cells were cultured in RPMI 1640 with 10% FBS, 10 
units/ml penicillin, 100μg/ml streptomycin at 37°C in 5% CO2. Prior to 
treatment, cells were plated in 24 well culture plates at a density of 2x106 
cells/well and cultured for 24h. 
 
5.1.4 Bone Marrow Derived Macrophages (BMDM)  
 
Mice were sacrificed through cervical dislocation. Total bone marrow was 
obtained from mice by flushing femurs and tibiae with Iscove's Modified 
Dulbecco's Medium (IMDM - Thermo Fisher Scientific). Cell suspension was 
incubated for 5’ at room temperature with ACK (Ammonium-Chloride-
Potassium) Lysis Buffer, used for the lysis of red blood cells, and then white cells 
were pelleted.  
Bone marrow mononuclear phagocytic precursor cells were propagated in 
suspension by culturing in macrophage medium IMDM containing 10% FBS 
(Thermo Fisher Scientific), 100units/ml penicillin and 100μg/ml streptomycin 
(Thermo Fisher Scientific), supplemented with 10ng/ml M-CSF (Miltenyi), or 
10ng/ml GM-CSF (Miltenyi) in tissue culture plates (Stanley, 1997). The cells 
were maintained at 37°C in a humidified incubator with 5% CO2. 
After 3 days half of the medium was replaced with a fresh one and after 7 days 
macrophages differentiated for the experiments were treated for different time 
period (24-48h) to polarize them. 
 
5.2 Macrophage treatment  
 
Human and murine MΦ were incubated for different time point (3, 6, 24h) with 
LPS 1μg/ml (Sigma) or IL-4 20ng/ml (Miltenyi) in combination with IL-13 
10ng/ml (Miltenyi) and MAO inhibitor Pargyline (100μM Sigma). To verify the 
involvement of MAPK p38 and transcription factor Sp1 in MAO expression, cells 
were incubated for 30’ before LPS and cytokine treatment with i) SB202190 
10μM, a specific p38 inhibitor and ii) mithramycin 5μM (Sigma), a specific 
inhibitor for Sp1 activation. All the used cytokines were specific for mouse or 
human samples. 
 
5.3 Denervation treatment 
 
Mice were injected intraperitoneally with 0.1mg/g mice weight 6-
hydroxydopamine-hydrochloride (6-0H-DOPA - Sigma) (Finch et al, 1973). The 
animals were sacrificed after 24h and their hearts were isolated and subjected to 
2 different protocol of oxidative stress. After the treatments hearts were frozen 
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for the following analysis. The chemical denervation was assessed through 
western blot analysis for every treated heart and for this purpose tyrosine-
hydroxylase antibody (Sigma) was used as typical marker to target synaptic 
terminals. 
 
5.4 Treatment protocols of oxidative stress 
 
Adult (aged 4 months) male C57BL/6 WT mice (Charles River, Padova, Italy) 
were sacrificed by cervical dislocation. Hearts were perfused with bicarbonate 
buffer gassed with 95% O2–5% CO2 at 37°C (pH 7.4) at a constant flux of 5 
ml/min. Perfusion was performed in the nonrecirculating Langendorff mode. 
The perfusion buffer contained (in mM) 118.5 NaCl, 3.1 KCl, 1.18 KH2PO4, 25.0 
NaHCO3, 1.2 MgCl2, 1.4 CaCl2 and 5.6 glucose. Hearts were treated as follows (n ≥ 
6/group): after 10’ of stabilization, hearts were subjected to i) 15’ of perfusion 
with 1mM H2O2; ii) 40’ of global ischemia by stopping the coronary flow and 15‘ 
of reperfusion. After these treatments, hearts were frozen in liquid nitrogen and 
stored at −80°C for analysis. Treatments were performed adding the MAO 
inhibitor pargyline (0.5 mM) to the perfusion buffer. 
 
5.5 Measurement of lactate dehydrogenase activity 
 
To determine the amount of lactate dehydrogenase (LDH) released from the 
hearts exposed to H2O2 or IR protocol, coronary effluent was collected at 1’ 
intervals during the 15’ of reperfusion as previously described. At the end of 
reperfusion hearts were collected and homogenized for assessing the residual 
activity of LDH in the whole tissue.  
Since all values were normalized to heart weight, the amount of LDH released 
was expressed as % of total (i.e, effluent + homogenate) to rule out possible 
changes due to variations in heart size. LDH activity was determined by 
spectrophotometrically measuring the absorbance of NADH at 340nm (reduction 
of pyruvate to lactate) according to the following reaction (fig. 8). 
 
 
Figure 8. Lactate dehydrogenase reaction. 
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5.6 Mass Spectrometry (MS) analysis 
 
Liquid chromatography tandem mass spectrometry analysis (LC-MS/MS) of 
metabolites in heart samples and neonatal rat ventricular myocytes were 
performed in collaboration with Dr. Alessandra Castegna (University of Bari, 
Italy). 
 
5.7 Fluorescence microscope 
 
5.7.1 Measurement of oxidative stress 
 
ROS concentration was measured using MitoTracker® Red CM-H2Xros (MTR, 
Thermo Fisher Scientific, λexc = 579 nm, λem = 599 nm) probe and the cationic 
dihydroethidium probe (DHE, Sigma, λexc = 518 nm, λem = 605 nm).  
MTR is a reduced dye, that passively diffuses across the plasma membrane and 
accumulate in active mitochondria. It does not fluoresce until it enters live cells, 
where it is oxidized by reactive oxygen species (ROS). MTR contains a mildly 
thiol-reactive chloromethyl moiety for labeling mitochondria The cells were 
seeded on 24mm coverslips and incubated for 30’ at 37°C with 20nM MTR in 
HBSS.  
DHE freely permeates cell membrane and when it is oxidized, mainly by 
superoxide anion, it becomes red fluorescent. Oxidized DHE binds to nuclear 
DNA, a process that results in a further increase in fluorescence. 
Heart slices were incubated for 30’ at 37°C with 5μM DHE in degassed PBS and 
then washed twice in PBS 1X. Considering that the solution is photosensible, all 
the operations were carried out in dark. 
For each analyzed coverslip DHE fluorescence intensity was calculated as the 
mean fluorescence of all the selected ROIs. 
Images were collected using a confocal microscope (Leica SP5), a 63X oil-
immersion objective and appropriate emission filters. 
 
5.8 Cytofluorimetric Analysis 
 
5.8.1 ROS measurements 
 
Cells were loaded with DCFDA 10μM (2′,7′-Dichlorofluorescin diacetate 
Sigma) for 30’ at 37°C. Cells were collected and centrifuged for 5’ at room 
temperature at 1500 rpm. Cells were resuspended in FACS buffer (PBS 1X, 
1%FBS) and 10,000 events/sample were analyzed using a FACSCanto® analyzer 
(Becton Dickinson). Dead cells were excluded from FACS analysis by adding 
propidium iodide (PI).  
Data were processed using the FACSDiva software.  
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5.8.2 Marker expression 
 
Viability and purity of macrophages were determined by flow cytometry analysis 
(BDFacsCanto, Becton Dickinson). Viability was assessed by staining the death 
cells with PI. The cell population negative for PI was analyzed further for CD68 
expression (>99%) a general marker for the total macrophage population. CD80 
marker was used to assess the correct expression of the pro-inflammatory M1 
MΦ, while CD163 marker was used for the anti-inflammatory M2 ones. 
Cells were detached and resuspended in FACS buffer, divided in different 
samples and incubated with CD68, CD86 and CD163 labelled antibodies 
(Beckton Dickinson) for 30’ at 4°C. At the end samples were washed, centrifuged 
for 5’ at room temperature at 1500rpm and resuspended in FACS buffer. The 
analyses were performed using the BDFACSDiva software. 
 
5.9 ELISA assay 
 
MΦ supernatants were collected after 7 days of plating and after the treatments 
to be tested in sandwich ELISA (Peprotech and Beckton Dickinson), according 
manufacturer’s instruction. 
 
5.10 Measurement of hydrogen peroxide formation and MAO activity 
 
Hydrogen peroxide formation was determined using Amplex Red. The assay is 
based on the detection of hydrogen peroxide generated during substrate 
catabolism in a horseradish peroxidase (HRP) coupled reaction (fig. 9) using 10-
acetyl- 3,7-dihyrdoxyphenoxazine (Amplex Red reagent, Molecular Probes). 
 
 
Figure 9. Hoseradish peroxidase reaction. 
 
For the measurements of hydrogen peroxide production from MAO activity the 
isolated enzyme was incubated in a standard buffer (KCl 120mM, MOPS/TRIS 
20mM, pH 7.4) in the presence of 5μM Amplex Red reagent and 4mg/ml HRP.  
The reaction was started adding 10, 50 or 100μM of Nτ-methylhistamine, 
histamine and tyramine as positive control. Fluorescence intensity was recorded 
for 10’ at 37°C using a Perkin Elmer LS-50B fluorimeter at the 544/590nm 
excitation/emission wavelengths. Parallel samples were run in the absence of 
substrate determine an eventual increase in fluorescence not due to MAO 
activity. 
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electrode. The electrode is constituted from a negatively charged platinum cathode 
and a positively charged silver anode immersed in a saturated KCl solution 
divided by a membrane selectively permeable to oxygen. Initially the medium was 
added to the chamber maintained t 37°C and continuously stirred. After the 
equilibration of the medium, 0.5 mg/ml mitochondria were added and oxygen 
consumption was followed for 2 minutes. T st co ounds at diff rent 
concentrations were added and after 3 minutes FCCP was added to induce 
maximal respiration and oxygen consumption monitored for another 3 minutes. 
 
4.4 Mea r ment of hydr g n peroxide formation and MAO 
activity 
Hydrogen peroxide formation was determine  using Amplex Red. The 
assay is based on the detection of hydrogen peroxide generated during substrate 
catabolism in a horsera ish peroxidase (HRP) coupled reaction using 10-acetyl-
3,7-dihyrdoxyphenoxazine (Amplex Red reagent, Molecular Probes) (Fig. 8).  
 
For the measurements of hydrogen p roxide production from the respiratory 
chain, mitochondria were incubated in a standard medium in the presence of 10 
mM Ampl x Red reagent and 15 mg HRP. The reaction was started by the addition 
of 5 mM succinate or 1 mM Antimycin A and monitored for 10 minutes at 37°C 
using a Perkin Elmer LS-50B fluorimeter at the 544/590 nm excitation/emission 
wavelengths. The velocity of H2O2 production was calculated from a calibration 
curve obtained adding known amounts of H2O2.
MAO activity was measured in the mitochondrial fraction following the 
same protocol. To discriminate between MAO A and B activity specific substrates 
and inhibitors for each isoform were used. Mitochondrial proteins were incubated 
O
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Figure 8. The mechanism of Amplex Red oxidation. 
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5.11 Cell extracts and western blot analysis  
 
5.11.1 Sample preparation 
 
2x106 cells for well were seeded in a 24-well plate and collected after the 
treatment. Cells were resuspended in 100μL of the following Lysis Buffer: NP-40 
1%, sodium deoxycholate 0.25%, EDTA 2mM, SDS 2%, 1X protease and 1X 
phosphatase inhibitor mix (Roche) in PBS 1X. Samples were homogenized by 
mechanical passages through the pipet and their protein concentration was 
determined with Bradford method (BioLegend). Then 33μL of Sample Buffer 4X 
(glycerol 20%, SDS 3%, Tris 75mM, bromophenol blue 0.02%, β-
mercaptoethanol 5% in H2O, pH 6.8) were added and the samples were heated at 
100°C for 10’. Finally they were loaded on the gel or stored at -20°C. 
 
5.11.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot 
 
Electrophoresis was performed on polyacrylamide gel prepared in glass labs 
0.75mm thick with 12% acrylamide in the separating gel and 5% in the stacking 
gel. The following solutions were used for the preparation of the gel and the 
electrophoresis run: 
 
Acrylamide/bisacrylamide: 30% acrylamide and 0.8% bisacrylamide 
Lower Tris-HCl (4X): 1.5 M Tris-HCl and 0.4% SDS, pH 8.8 
Upper Tris-HCl (4X): 0.5 M Tris-HCl and 0.4% SDS, pH 6.8 
Running buffer (4X): 0.1 M Tris-HCl, 0.77 M glycine and 0.4% SDS, pH 8.3 
 
Gel polymerization was obtained by the addition of TEMED (Applichem) and 
ammonium persulfate 0.1mg/ml (Applichem). Samples were run on the gel at 
room temperature using an Electrophoresis Power Supply (Apelex) that 
provided a constant voltage of 70V in the stacking gel and 150V in the separating 
gel. 
In order to make the proteins accessible to antibody detection, they were moved 
from the gel onto a nitrocellulose membrane. A 0.45μm nitrocellulose membrane 
(BioRad Laboratories) was placed on top of the gel, avoiding bubbles, and placed 
on top. This sandwich was then inserted into a transfer box filled with Transfer 
Buffer, so that the gel is oriented towards the cathode and the membrane 
towards the anode. When a current is applied to the electrodes, this causes the 
proteins to migrate from the negatively charged cathode to the positively 
charged anode, i.e. towards the membrane. Proteins were transferred for 18h at 
150mA at 4°C.  
Once the transfer was carried out, the membrane was saturated with fat-free 
milk 5% in TBS (Tris-HCl 50mM, NaCl 150mM, pH 7.5) Tween 0.1% for 1h at 
room temperature. The antibodies used to detect the proteins of interest were 
diluted in milk 0.1% or BSA 3% in TBS-Tween 0.1%. The following primary 
antibodies were used: 
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Rabbit Anti-MAO-A (AbCam), dilution 1 : 1000  
Rabbit Anti-MAO-B (Sigma), dilution 1 : 1000 
Mouse Anti β-actin (Sigma), dilution 1 : 5000 
Rabbit Anti histidine-decarboxylase (Sigma), dilution 1:500 
Rabbit anti-tyrosin-hydroxilase (Sigma), dilution 1:1000 
Rabbit anti-Phospho-p42/44(Erk) (Cell signaling) 1:2000 
Rabbit anti-p42/44(Erk) (Cell signaling) 1:1000 
 
All the primary antibody incubations were carried out overnight at 4°C upon 
gently shaking. Following the incubation, membranes were washed 3 times for 
10’ with TBS-Tween 0.1%. Secondary antibodies were diluted in TBS-Tween 
0.1% and incubated with the membrane for 1h at room temperature. 
Fluorochrome‐conjugated secondary antibodies used were: 
 
Rabbit Anti-Mouse (LICOR), dilution 1 : 10000  
Mouse Anti-Rabbit (LICOR), dilution 1 : 10000 
 
Finally membranes were washed 3 times for 10’ with TBS 1X and detection was 
performed with the Odyssey Infrared Imaging System (LICOR Biosciences). 
 
5.11.3 Densitometry 
 
Images of the acquired western blots were analyzed using the Image J software. 
This program allows the quantification of the optical density of bands or dots 
that is directly proportional to the protein content. 
 
5.12 Statistics 
 
Results are presented as mean ± SEM. When the experiment was repeated more 
than 3 times, comparisons between two groups of data were performed via 2-
tailed unpaired Student t test. A P-value less than 0.05 was taken to indicate a 
significant difference that was then tagged with an asterisk. 
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6. AIMS OF THE STUDY  
 
The first aim of this study was to clarify the mechanisms that induce MAO 
activation in conditions of oxidative stress and cardiac injury. The increased 
MAO activity can be attributed to (i) an increase in its expression, (ii) post-
translational modifications and/or (iii) increased availability of substrates. 
However, cardiac MAO expression hardly changes in several pathophysiological 
conditions and covalent modifications cause just minor changes of their activity. 
Therefore, to test the third hypothesis, identification and quantification of MAO 
substrates were performed in ex vivo and in vitro model of cardiac injury, i.e. 
Langendorff-perfused mouse hearts and neonatal rat ventricular myocytes, 
respectively. Two different protocols of oxidative stress were set up in the ex vivo 
model. Mass spectrometry (MS) analyses, ROS measurements and viability 
assays allowed to identify and quantitate for the first time a range of metabolites 
involved in these protocols. Our attention was focused on the most abundant 
substrate of MAO that was found in our experimental models, Nτ-
methylhistamine (NMH), which originates from histamine methylation and 
represents the main product of its intracellular catabolism. The potential sources 
of histamine were characterized, considering both myocyte and non-myocyte 
origin. To this aim synaptic terminals were considered as non-myocyte sources 
and we excluded them by a protocol of chemical denervation. Then 
cardiomyocyte was analysed as possible source in the in vitro model. 
Furthermore, we investigated the mechanisms underlying histamine 
involvement in MAO activation in isolated cardiomyocytes assessing its 
contribution in ROS production. 
In the second part of the work we focused our attention on the role of MAO in 
phagocytic cells, as macrophages (MΦ) largely contribute to cardiac pathologies 
by ROS formation, cytokine release, tissue healing and cellular recruitment. 
Although it is well-known that ROS play a key role in MΦ differentiation and 
activation, the sources of ROS involved in these processes are still unclear. Thus 
we hypothesized that MAO could be involved in the regulation of MΦ 
metabolism. To this aim MAO expression and its corresponding pathway of 
induction were investigated and characterized. Next, the contribution of MAO in 
ROS formation was assessed during differentiation and polarization processes. 
For this purpose, we assessed its contribution by means of ROS level 
measurements after treatment with differentiating stimuli (GM-CSF, MCSF) and 
also under polarization stimuli (LPS, IL-4 and IL-13). Cytofluorimetric analyses 
and ELISA assays were performed to assess the phenotypic MΦ differentiation to 
M1 or M2 subtype and these enabled to evaluate MAO inhibition effects on 
differentiation process.  
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7. RESULTS 
 
7.1 The increased availability of MAO substrates upon oxidative stress 
induces MAO activation in perfused isolated hearts 
 
It has been demonstrated that MAOs contribute to the oxidative stress occurring 
in hearts subjected to pathological conditions, such as cardiac reperfusion injury 
and decompensated hypertrophy, and that their inhibitors significantly protect 
the heart in these models. However, the molecular mechanisms underlying MAO 
activation are still unclear. 
For this reason, in collaboration with the University of Bari, we quantitated and 
identified amines, potential MAO substrates, by MS analysis in mouse 
Langendorff perfused hearts subjected to two protocols of oxidative stress. We 
exploited the following procedures: (i) 1mM H2O2 perfusion for 15’ and (ii) 40’ 
ischemia followed by 15’ reperfusion (IR). 
The comparison of the amine contents, in the absence and presence of MAO 
inhibition, allowed the identification of the molecules that are potentially 
oxidized by this enzyme. 
 
7.1.1 Oxidative stress protocol by H2O2 perfusion 
 
 
 
Figure 10. Identification and quantification of MAO substrates in hearts perfused with 
H2O2. Isolated mouse hearts were Langendorff-perfused in the absence and presence of 
pargyline (0.5mM) added 10’ before the perfusion with a buffer containing H2O2 (1mM). In 
parallel, hearts were perfused in the absence of H2O2. They were frozen in liquid N2 and analysed 
by MS. *p<0.05, **p<0.01 
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The MAO inhibitor pargyline, added to the perfusion buffer 10’ before the 
protocol of oxidative stress, caused a relevant increase in the heart content of 
typical MAO substrates: 5-HT, NE as well as Nτ-methylhistamine (NMH) and its 
precursor histamine (HA) (fig. 10). It is worth mentioning that NMH represented, 
together with its precursor, HA, the most abundant amine that accumulates in 
this experimental model of cardiac injury. Furthermore, the accumulation of 
MAO substrates upon pargyline exposure correlated with a reduced MAO-
dependent production of H2O2, as detected by DHE staining in heart cryosections 
(fig. 11). 
 
 
 
Figure 11. ROS levels upon H2O2 heart perfusion is decreased by MAO inhibition. Isolated 
mouse hearts were Langendorff-perfused in the absence and presence of pargyline (0.5mM) 
added 10‘ before the perfusion in the absence or in the presence of H2O2 (1mM). Heart slices 
were incubated 20’ with DHE (5μM) and visualized by fluorescence microscopy. Fluorescence 
intensity was quantified using ImageJ software. *p<0.05 vs control 
 
The correlation between the decreased ROS formation in the presence of 
pargyline (fig. 11) and the corresponding accumulation of MAO substrates, 
suggests that H2O2 perfusion acts as a trigger for MAO activity increasing the 
availability of its substrates. Indeed, several studies indicate H2O2 as a key 
modulator and inducer of different metabolic pathway, supporting the idea that 
ROS could represent an important trigger also for MAO, in physiological and 
pathological conditions. 
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7.1.2 Oxidative stress protocol by IR 
 
The increase in MAO substrates upon pargyline addition was observed also in 
hearts subjected to a second protocol of oxidative stress, i.e. post-ischemic 
reperfusion. In particular NMH (fig. 12a) and HA (fig. 12b) represented the most 
abundant amines accumulating in these hearts pre-treated with the MAO 
inhibitor, as in the protocol of H2O2 perfusion. 
These results provide evidence for a role of HA metabolism in MAO activation. 
 
 
Figure 12. NMH and HA content in hearts perfused by IR protocol. Isolated mouse hearts 
were Langendorff-perfused in the absence and presence of pargyline (0.5mM) added 10‘ before 
the perfusion in aerobiosis or ischemia (40’) followed by reperfusion (15’). a) NMH and b) HA 
were quantitated by MS. *p<0.05 vs control 
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7.2 HDC is expresses in isolated cardiomyocytes 
 
 
 
Figure 13. HDC expression in isolated cardiomyocytes HA is derived from histidine 
decarboxylation by L-histidine-decarboxylase (HDC) and then it is modified by histamine-N1-
methyltransferase (HNMT) in its metabolite Nτ-methylhistamine (NMH). Isolated NRVMs were 
lysed and separated by SDS/PAGE. Two bands, corresponding to the inactive form of the enzyme 
(74kDa) and to the active one (60kDa), were detected by western blot with anti-HDC antibody. 
 
The scheme for HA metabolism (fig.13 left panel) reports the involved enzymes 
and, importantly, recalls that NMH is a MAO substrate, whereas HA is not, as 
reported in literature.178, 179, 180 
It has already been verified that histidine-decarboxylase (HDC) and histamine-N-
methyltransferase (HNMT) are expressed in heart homogenates.181 In addition 
we provided evidence that also isolated cardiomyocytes are able to express HDC 
enzyme (fig. 13 right panel), providing HA themselves.  
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7.3 Cardiomyocyte as MAO substrate source 
 
To evaluate whether isolated cardiomyocytes synthesize MAO substrates, 
potentially promoting MAO activity, we analysed isolated NRVM by MS. 
 
 
 
Figure 14. Amine content in isolated neonatal cardiomyocytes. The identification and 
quantitation of the amines contained in NRVMs (5x10^6cell/plate) were performed by MS 
analysis. 
  
HA, NMH and epinephrine were found to be the most abundant amines in 
isolated cells (fig. 14), underlying a potential role for HA metabolism in the heart. 
Moreover, these data suggest the hypothesis that cardiac myocytes could 
promote MAO activity by synthesizing its specific substrates, i.e. NMH and 
epinephrine upon oxidative stress. 
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7.3.1 Oxidative stress in vitro  
 
To test this hypothesis, the amine levels were quantitated in NRVMs exposed to 
H2O2 for 1h in the absence and presence of pargyline. 
 
 
Figure 15. NMH and HA quantification in isolated NRVMs subjected to oxidative stress 
conditions. We quantitated by MS analysis a) NMH and b) HA content in NRVMs 
(5x10^6cell/plate) after 1h incubation with H2O2 (100μM) in the absence and presence of 
pargyline (Parg 100μM). *p<0.05  
 
MS analysis showed that, in conditions of oxidative stress, NMH accumulated 
upon MAO inhibition (fig. 15a), as in the ex vivo model, indicating H2O2 as a 
trigger for MAO activity. These results paralleled the decreased ROS levels due to 
pargyline, that was previously demonstrated in Prof. Di Lisa’s laboratory (not 
shown). 
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7.4 Identification of MAO non-myocyte sources in the heart  
 
To investigate the contribution of non-myocyte sources of MAO substrates under 
oxidative stress conditions we focused our attention on the synaptic terminals 
that innervate heart and commonly represent a pivotal source of 
neurotransmitters. For this purpose, mice were denervated by i.p. injection with 
6-hydroxydopamine (6-OH-DOPA), a neurotoxic drug that deletes 
catecholaminergic neurons. After 24h hearts were excised and subjected to the 
IR protocol in the absence and presence of pargyline. To verify the efficacy of the 
denervation protocol, cardiac homogenates were tested by western blot for 
tyrosine hydroxylase (TH) (fig. 16), a functional marker for synaptic terminals.  
 
 
 
Figure 16. Denervation efficacy was assessed by tyrosine hydroxylase (TH) western blot. 
Mice injected with 6-OH-DOPA (0.1mg/g mouse weight) or with vehicle were sacrificed after 24h 
and subjected to aerobic perfusion or IR protocol. Denervation efficacy by 6-OH-DOPA (0.1mg/g 
mouse weight) was assessed by western blot analysis for TH antibody. Heart excised by 
denervated and vehicle-treated mice were homogenated and separated by SDS/PAGE. Band 
intensities were quantified by densitometry using ImageJ software and normalized to α-actin to 
check protein loading. *p<0.05 vs control 
 
A significant decrease of TH protein levels was observed after 24h of 
denervation (fig. 16). 
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7.4.1 Synaptic terminals significantly contribute to MAO substrate availability 
 
Denervated and vehicle-treated hearts were then analyzed by MS to quantitate 
MAO substrates. 
 
 
Figure 17. MAO substrate content in denervated hearts as compared to vehicle-treated 
controls. Mice injected with 6-OH-DOPA (0.1mg/g mouse weight) or with vehicle were sacrificed 
after 24h and subjected to aerobic perfusion or IR protocol. MS analyses were subsequently 
performed to identify and quantitate MAO substrates: a) NE, b) epinephrine, c) NMH, d) HA. 
*p<0.05, **p<0.01 
 
The analysis showed significant differences between denervated and vehicle-
treated hearts. Upon IR treatment, denervated hearts displayed NE, epinephrine 
and NMH decrease as compared to vehicle-treated hearts (fig. 17a-b-c). However 
HA content was not significantly decreased by denervation. We considered that 
other HA sources in heart tissue, such as mast cells,182 are not affected by 
chemical denervation, so they can balance the synaptic terminal contribution, 
justifying the mild decrease of HA upon denervation (fig. 17d). 
Taken together, our findings showed that synaptic terminals represent one of the 
main non-myocyte sources for MAO substrates under oxidative stress conditions. 
Furthermore, LDH assay of the related effluents indicates a protective effect 
linked to denervation treatment (fig. 18), already discussed in other papers.182, 
184, 185 The protection correlated to the decreased substrate availability for MAO 
activity. Indeed, these data demonstrate that under pathological conditions a 
larger availability of substrates fuels MAO activity exacerbating ROS formation, 
which plays a crucial role in IR-induced injury. 
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Figure 18. Denervated hearts are protected against IR-induced injury. Mice injected with 6-
OH-DOPA (0.1mg/g mouse weight) or with vehicle were sacrificed after 24h and subjected to 
aerobic perfusion or IR protocol in the absence and presence of pargyline (0.5mM). Effluents 
collected during post-ischemic reperfusion (40’-15’) were analyzed by LDH assay to quantitate 
lactate dehydrogenase release. ***p<0.001 
 
To better characterize the relevance of HA and NMH in injured hearts, we 
evaluated the contribution of other sources besides synaptic terminals. For this 
purpose we subjected denervated hearts to IR protocol in the presence and 
absence of pargyline. 
 
 
 
Figure 19. NMH and HA content in denervated hearts in comparison to vehicle-treated 
controls upon MAO inhibition. Mice injected with 6-OH-DOPA (0.1mg/g mouse weight) or with 
vehicle were sacrificed after 24h and subjected to ischemia (40’) followed by reperfusion (15’) in 
the absence and presence of pargyline (0.5mM). MS analysis were subsequently performed to 
quantitate a) NMH and b) HA. *p<0.05 
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MS analyses suggest that, although synaptic terminals give a relevant 
contribution to NMH availability (fig. 17c), other sources promote MAO activity 
as demonstrated by the corresponding accumulation upon MAO inhibition (fig. 
19a). However, its extent of accumulation is lower as compared to non 
denervated hearts. The other sources can be represented by immune cells () and 
also by cardiomyocytes themselves, as reported (fig. 14). 
 
7.5 HA contribution to induce oxidative stress in vitro through MAO 
activation 
 
To elucidate the mechanism underlying the effect of HA and its metabolite in 
determining oxidative stress, NRVMs were exposed to HA in the absence or 
presence of pargyline.  
 
 
 
Figure 20. NMH and HA content in isolated NRVMs upon HA exposure in the presence or 
absence of MAO inhibition. By MS analysis a) NMH and b) HA content was quantitated in 
NRVMs (5x10^6cell/plate) incubated 1h with HA (50μM) in the absence and presence of 
pargyline (Parg 100μM). *p<0.05 
 
HA addition to NRVMs caused its own intracellular increase (fig 20b). This 
indicates that HA is transported, through the OCT3 amine transporter into the 
cardiomyocytes.186, 187 Importantly, the increased levels of HA are accompanied 
by NMH formation, that becomes evident in the presence of pargyline. 
In parallel we also performed ROS measurements of NRVMs incubated with HA. 
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Figure 21. ROS level measurement in NRVMs after HA exposure. NRVMs were treated for 1h 
with HA (50µM) in the absence and presence of pargyline (100µM) or famotidine (10µM). 
Inhibitors were added 30’ before the treatment. ROS levels were visualized by means of 
MitoTracker® Red CM-H2Xros (MTR)(20nM) fluorescence using a 63X objective. *p<0.05 
 
HA induced an increased ROS formation that was reduced in the presence of 
pargyline (fig. 21). Taken together, these data support the hypothesis that NMH 
availability increases due to the activation of HA metabolism, i.e. HA enters into 
cardiomyocytes and is metabolized to NMH that, in turn, fuels MAO activity. 
We also considered that HA activates its specific receptor 2, expressed on the 
plasma membrane of cardiomyocytes, to increase vascular permeability and 
induce apoptosis.188, 189 Therefore, to verify the potential contribution of the 
histamine-2-receptor (H2R) pathway in the increase of ROS levels, its activation 
was tested by means of a specific inhibitor, famotidine.190, 189 Famotidine did not 
significantly reduce the HA-dependent ROS level induction (fig. 21), providing 
evidence that the H2 receptor-dependent mechanism does not play a major role 
in the MAO-dependent oxidative stress induced by histamine. 
HA 
Parg+HA  Fam+HA 
CT 
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7.6 MAO in human Monocytes/Macrophages 
 
It has been largely shown that inflammation is usually involved in cardiac 
diseases and cells involved in inflammatory response such as mast cells, 
monocytes, macrophages (MΦ), might release substrates for MAO activity and 
consequently increase the oxidative stress. Furthermore, MAO itself may 
contribute to ROS production inside immune phagocytic cells, on which we 
focused our attention. 
As already described in the Introduction, the role of MAO in phagocytic cells has 
not been clearly defined.105 Thus, to better characterize MAO role in phagocytic 
cells, we investigated MAO-dependent H2O2 involvement in MΦ development 
and activity. 
Firstly, MAO protein levels were measured in human monocytes (Mn) and MΦ, 
M1 and M2, by Western blot. 
 
 
Figure 22. MAO-A and –B expression levels in human Mn in comparison to derived MΦ. Mn 
were isolated from buffy coat as previously described in Material and Methods. 200x10^6 cells 
were lysed immediately after isolation (Mn). 2x10^6 Mn perwell were plated and differentiated 
in MΦ, M1 and M2, for seven days in presence of the specific stimuli, GM-CSF (100ng/ml) and M-
CSF (100ng/ml) respectively. Band intensities were quantified by densitometry using ImageJ 
software and normalized to β-actin to check protein loading. *p<0.05 vs Mn 
 
Both MAO-A and –B isoforms were expressed in M1 and M2 differentiated MΦ, at 
difference of their precursor Mn that displayed low levels of the enzyme. M1 MΦ 
expressed lower MAO protein levels than the M2 population, and the A isoform 
showed significant differences (fig. 22a) whereas the isoform B did not show 
significant increases (fig. 22b). 
Based upon the literature we polarized cells in different ways to evaluate MAO-A 
expression: we compared IL-4 and IL-13 combinatorial treatment (IL-4+IL-13), 
which are anti-inflammatory stimuli, to LPS exposure, that is a pro-inflammatory 
one. 
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7.6.1 Pro-inflammatory and anti-inflammatory stimulus induction of MAO-A 
expression in human M2 MΦ 
 
Firstly, we polarized differentiated MΦ with LPS and assessed the expression of 
MAO-A, the most relevant isoform as previously demonstrated (fig. 23). 
LPS is a common stimulus used to simulate an inflammatory state that polarizes 
MΦ through TLR4 activation.191 
 
 
 
Figure 23. MAO-A expression levels in polarized MΦ M2. M2 MΦ were incubated with 
different doses of LPS (0.2, 1μg/ml) for 24h. After LPS exposure cell lysates were separated by 
SDS/PAGE and tested by western blot for MAO-A antibody. Band intensities were quantified by 
densitometry using ImageJ software and normalized to β-actin to check protein loading. *p<0.05 
vs control 
 
By western blot analysis we demonstrated that LPS induces MAO-A expression 
in a dose-dependent manner in M2 MΦ (fig. 23).  
These data support and validate recent studies that propose MAO-A as a possible 
marker for M2 MΦ.106, 107, 109 Therefore, we compared LPS treatment to IL-4+IL-
13 exposure in M2 MΦ, to assess the protein level induction linked to opposite 
stimuli. 
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Figure 24. MAO-A expression levels in polarized M2 MΦ upon pro- and anti-inflammatory 
stimuli. Cells differentiated in M2 MΦ were incubated for 24h with LPS (1μg/ml) or with IL-4 
(20ng/ml) and IL-13 (10ng/ml). At the end of the treatment cell lysates were separated by 
SDS/PAGE and tested by western blot for MAO-A antibody. Band intensities were quantified by 
densitometry using ImageJ software and normalized to β-actin to check protein loading. *p<0.05, 
**p<0.01 
 
IL-4 and IL-13 combination induced higher protein levels as compared to LPS 
exposure. This result indicates that both stimuli (i) LPS and (ii) interleukin 
combination represent MAO inducers, even if they are commonly thought to 
promote opposite polarizations, pro- and anti-inflammatory respectively.  
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7.6.2 MAO-A induction pathway in human M2 MΦ 
 
LPS and IL-4+IL-13 treatments have been reported to induce a MAPK cascade 
through the activation of their corresponding receptors. Among these kinases 
p38 MAPK has been shown to be involved in Sp1 activation in phagocytic 
cells.192, 193, 194 Furthermore, as reported in the Introduction, this transcription 
factor induces MAO expression.123, 124, 125, 126 Therefore, we hypothesized a 
possible MAO-A induction pathway that involves these two factors: p38MAPK 
and Sp1 factor. To verify this hypothesis, two specific inhibitors were used: 
SB202190, a p38 inhibitor, and mithramycin, a specific Sp1 inhibitor. M2 MΦ 
were exposed to both the activation treatments (LPS and IL-4+IL13) in the 
absence and presence of the two corresponding inhibitors.  
 
  
 
Figure 25. MAO-A expression levels in polarized M2 MΦ upon pro- and anti-inflammatory 
stimuli in the presence and absence of MAPK p38 inhibitor and Sp1 factor inhibitor. Cells 
differentiated in M2 MΦ were pre-treated for 30’ with SB202190 (5μM) or mithramycin (100nM) 
and then incubated 24h with LPS (1μg/ml) or IL-4 (20ng/ml) and IL-13 (10ng/ml). At the end of 
the treatment cell lysates were separated by SDS/PAGE and tested by western blot for MAO-A 
antibody. Band intensities were quantified by densitometry using ImageJ software and 
normalized to β-actin to check protein loading. *#p<0.05  
 
Western blot proved that p38 and Sp1 inhibitors prevented MAO expression 
upon both the treatments, LPS and IL4+IL-13 (fig. 25), validating our 
hypothetical induction mechanism. 
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Figure 26. Scheme of MAO induction pathway in MΦ M2 upon LPS and IL-4+IL-13 
treatments. 
 
These latter results describe a new pathway of MAO-A induction in M2 MΦ (fig. 
26). Moreover, these data suggest that MAO may be involved in 
physiopathological MΦ processes. 
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7.6.3 MAO role in human MΦ differentiation 
 
It is known from the literature that ROS are involved in MΦ differentiation.89, 92 
Therefore, we speculated a possible role for MAO-A-dependent ROS production 
during cell development process. We measured MAO-A expression during the 
differentiation period of 7 days. 
 
 
 
Figure 27. Time-dependent expression of MAO-A along M2 MΦ differentiation. Cells were 
incubated in presence of M-CSF (100ng/ml) and every two days were collected to verify MAO-A 
expression levels. At the end of the treatment cell lysates were separated by SDS/PAGE and 
tested by western blot for MAO-A antibody. Band intensities were quantified by densitometry 
using ImageJ software and normalized to β-actin to check protein loading. **p<0.01, ***p<0.001 vs 
day 1 
 
These experiments showed that MAO-A induction is time-dependent (fig. 27) 
and that it reaches appreciable expression levels since the third day of 
differentiation. 
As detailed in the Introduction (4.6.4), ROS are key regulators of MΦ 
differentiation. Thus, to understand if MAO could contribute to phagocytic cell 
development by its H2O2 production, we measured ROS levels in both MΦ M1 
and M2 at the seventh day of differentiation. 
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Figure 28. MAO-dependent H2O2 contributes to redox homeostasis of differentiated M2 
MΦ. Cells were treated during the differentiation period in the presence and absence of 
pargyline (100μM). At the seventh day they were incubated for 30’ with DCFDA (10μM) before 
the cytofluorimetric analysis. Dying cells were excluded by the use of Propidium Iodide, as 
described in Materials and Methods (5.8.1). *p<0.05 
 
Pargyline reduced ROS levels only in M-CSF-differentiated M2 MΦ, and not in 
GM-CSF differentiated M1 (fig. 28b). These results indicate that MAO-dependent 
H2O2 contributes to ROS homeostasis of differentiated M2 MΦ, suggesting a role 
for MAO in the development of M2 phenotype. To verify this hypothesis we 
tested the expression of two specific markers, CD80 and CD163, corresponding 
to the M1 and M2 phenotype, respectively.195, 196 These two proteins are 
expressed on MΦ plasma membrane and they represent targets to distinguish 
the two MΦ populations. 
 
 
 
Figure 29. MΦ markers expression in the presence and absence of pargyline. After seven 
days of differentiation in the presence or absence of pargyline (100μM) M1 and M2 MΦ either 
have been tested using specific FITC-conjugated antibody for a) CD80 (M1) and b) CD163 (M2). 
Cells were detached and incubated for 30’ in ice with the corresponding antibodies. Samples 
were analysed by cytofluorimetry. Dying cells were excluded by the use of Propidium Iodide, as 
described in Materials and Methods (5.8.2). *p<0.05  
 
MAO inhibition decreased CD163 expression (fig. 29b), while it did not affect 
CD80 (fig. 29a), supporting data that linked MAO activity to M2 phenotype. 
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Therefore, ROS level decrease (fig. 28b) and CD163 reduced expression (fig. 29b) 
suggest that MAO activity contributes to M2 MΦ development. 
To define that MAO-dependent ROS production is involved in M2 MΦ 
differentiation, we considered a possible interaction with one of the most 
common MAPK involved in cell development and homeostasis, ERK. 
M-CSF has been reported to induce ROS production through its specific receptor 
197 that leads to a MAPK cascade involving ERK activation.89, 198, 199 However, the 
mechanism that induces ROS formation and activates this signalling remains 
unclear. Thus we evaluated ERK phosphorylation in the absence and presence of 
pargyline during differentiation. 
Based on MAO-A expression levels along M2 MΦ differentiation (fig. 27), we 
considered day 5 and 7. 
 
 
 
Figure 30. ERK expression and activation during M2 MΦ differentiation. Cells were treated 
during the period of differentiation in the presence and absence of pargyline (100μM). M2 MΦ 
were collected at the fifth and seventh day. Cell lysates were separated by SDS/PAGE and tested 
by western blot for ERK antibodies (anti-Phospho-p42/44(ERK) / anti-p42/44(ERK)). Band 
intensities were quantified by densitometry using ImageJ software. *p<0.05  
 
M2 MΦ at the seventh day did not show any difference between cells treated or 
untreated with MAO inhibitor, instead at the fifth day of differentiation a 
significant decrease in ERK phosphorylation occurred (fig. 30). These data 
provide evidence the involvement of MAO activity in MΦ M2 differentiation and 
its implication in ROS-dependent ERK MAPK activation.89 At the end of M2 MΦ 
differentiation (day 7) pargyline did not display any effect on ERK 
phosphorylation. This indicates that the maximal activation of ERK activity 
occurs at the fifth day of differentiation, when cells are exposed to M-CSF. 
Indeed, as described in Material and Methods (5.1.2), at the fifth day of 
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differentiation half part of the medium was changed. Therefore, new M-CSF 
addition to the cells led to ROS-dependent ERK MAPK activation.89 
7.6.4 MAO role in human MΦ polarization 
 
Given the increased MAO expression previously shown upon MΦ activation by 
LPS (fig. 25), we hypothesized that MAO-dependent H2O2 could contribute to MΦ 
ROS production both for bactericidal activity and MΦ homeostasis. To this aim 
M1 and M2 MΦ were treated with LPS for increasing time and the corresponding 
ROS levels were measured. 
 
 
Figure 31. MAO contributes to M2 MΦ polarization by its H2O2 production upon LPS 
exposure. Cells were treated for increasing time with LPS (1μg/ml) in the presence and absence 
of pargyline (100μM). They were incubated for 30’ with DCFDA (10μM) before the 
cytofluorimetric analysis. Dying cells were excluded by the use of Propidium Iodide, as described 
in Materials and Methods (5.8.1). *p<0.05 vs 3h parg-LPS, ##p<0.01 vs 1h LPS 
 
In the absence of LPS M1 pro-inflammatory MΦ produced high levels of ROS as 
compared to M2 MΦ (values not reported), however only M2 MΦ showed a 
significant increase of ROS levels upon LPS treatment and a relevant reduction at 
3h upon pargyline exposure (fig. 31b). 
Based upon a recent study of Bhattacharjee and coworkers,109 we investigated 
also if IL-4+IL-13 treatment could induce MAO-dependent ROS formation, 
supported by the addition of a typical MAO substrate, tyramine. However, no 
significant ROS increase was measured in our experiments in opposite to 
Battacharjee (data not shown). Probably this disagreement is due to the different 
protocol of cell differentiation and polarization that we used.109 
Given the ROS decrease at 3h LPS treatment in presence of pargyline (fig. 33b), 
we tested a possible correlation between this effect and M2 MΦ polarization 
process. To this aim we performed ELISA assay for two specific cytokines IL-10 
and IL-6. 
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Figure 32. IL-10 in MΦ M2 under LPS treatment. 2x10^6 M2 MΦ perwell were polarized in the 
presence and absence of LPS (1μg/ml) in the absence and presence of pargyline (100μM). After 
3h, supernatants were collected and IL-10 was quantitated by ELISA assay. *p<0.05 
 
IL-10 represents an anti-inflammatory cytokine released by MΦ M2, which was 
reduced upon MAO inhibition as shown (fig. 32). IL-10 is generally considered an 
anti-inflammatory cytokine, because it blocks the production of pro-
inflammatory cytokines and the capacity of myeloid cells to efficiently activate T-
cells.200, 201, 202, 203 
 
 
 
Figure 33. IL-6 in M2 MΦ under LPS treatment. 2x10^6 M2 MΦ per well were polarized in the 
presence and absence of LPS (1μg/ml) in the absence and presence of pargyline (100μM). After 
3h, surnatants were collected and IL-6 was quantitated by ELISA assay. *p<0.05 
 
Also IL-6 release was decreased upon MAO inhibition (fig. 33). Although this 
cytokine is classically considered as a pro-inflammatory one, several papers has 
demonstrated its anti-inflammatory activity.204, 205 IL-6 can promote 
regeneration and protection during infection and inflammation and on the other 
hand, this interleukin is needed for the activation of the immune system 
promoting mononuclear cell recruitment and T-cell apoptosis inhibition.204 
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Taken together, these findings (fig. 32-33) indicate that MAO is involved in M2 
MΦ polarization, according to the ROS measurements obtained in the same 
conditions (fig. 31b). 
 
7.7 MAO in murine models 
 
In parallel to human MΦ we evaluated RAW264.7 immortalized murine cell line 
and BMDM primary culture. Our aim was to compare MAO activity and roles 
between the two organisms, human and mouse, to characterize the differences 
between the models. Moreover, we wanted to optimize the condition to study 
MAO role in phagocytic cells, due to the high variability of primary cultures. 
 
7.7.1 MAO expression in RAW 264.7 
 
By western blot analysis we assessed MAO expression after 24h of LPS exposure. 
 
 
 
Figure 34. MAO-A and –B expression levels in murine MΦ cell line (RAW264.7) exposed to 
LPS. Cells were plated for 24h in the absence and presence of LPS (1μg/ml). At the end of the 
treatment cell lysates were separated by SDS/PAGE and tested by western blot for MAO-A 
antibody. Band intensities were quantified by densitometry using ImageJ software and 
normalized to red ponceau to check protein loading. 
 
Both the isoforms are expressed in RAW cells, however MAO levels did not 
increase upon LPS treatment (fig. 34), indicating a different responsiveness 
between primary human culture and immortalized murine cells. 
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7.7.2 MAO-A expression in M2 murine BMDM. 
 
We assessed MAO-A expression levels at 24h and 48h in BMDM. 
 
 
 
Figure 35. MAO-A and –B expression levels in murine M2 BMDM exposed to LPS treatment. 
Cells were plated for 24h and 48h in the absence and presence of LPS (1μg/ml). At the end of the 
treatments cell lysates were separated by SDS/PAGE and tested by western blot for MAO-A 
antibody. Band intensities were quantified by densitometry using ImageJ software and 
normalized to β-actin protein loading. 
 
BMDM respond to LPS and IL-4+IL-13 treatment in a similar way to human MΦ 
but with a different kinetics, i.e. after 48h of exposure (fig. 35). These data 
suggest that MAO may act in a similar way both in human and murine primary 
culture. 
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7.7.3 MAO role in murine M2 BMDM differentiation 
 
In order to characterize the role of MAO to BMDM differentiation, we performed 
ROS measurements at the end of the differentiation process in the presence and 
absence of pargyline. 
 
 
 
Figure 36. ROS levels in differentiated BMDM M2 MΦ at 7 days. Cells were differentiated 
with murine M-CSF (100ng/ml) specific stimulus, in the presence and absence of pargyline 
(100μM). At the seventh day cells were incubated for 30’ with DCFDA (10μM) probe, before 
cytofluorimetric analysis. Dying cells were excluded by the use of Propidium Iodide, as described 
in material and methods chapter. *p<0.05 
 
M2 BMDM, as observed in human M2 MΦ, showed a decrease of ROS level 
reduction in the presence of pargyline (fig. 36), supporting a role for MAO also in 
mouse model in BMDM differentiation. 
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7.7.4 MAO role in murine M2 BMDM polarization 
 
To test MAO involvement in M2 polarization, BMDM were exposed to LPS 
treatment for three hours at the seventh day as human samples. Furthermore, 
we performed the same experiment in parallel with the 48h treatment to assess 
MAO expression (fig. 35). At the end of these treatments, ROS measurements 
were performed by cytofluorimetric analysis.  
 
 
 
Figure 37. ROS levels in M2 BMDM in the presence and absence of MAO inhibition at 
different time point. Cells were treated for increasing time with LPS (1μg/ml) in the absence 
and presence of pargyline (100μM) and incubated for 30’ with DCFDA (10μM) before 
cytofluorimetric analysis. This kind of experiment was performed at the seventh and the eighth 
day of BMDM differentiation. Dying cells were excluded by the use of Propidium Iodide, as 
described in material and methods chapter. 
 
By these preliminary results it is likely to conclude that BMDM could respond as 
human MΦ, even if they report different time reactivity. Indeed, BMDM upon LPS 
exposure reached a peak at three hours that is blunted by pargyline (fig. 37a-b). 
However, it is necessary to deepen these studies to better characterize the 
differences between the phagocytic cells of the two organisms (human and 
mouse) and the MAO-related role. 
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8. CONCLUSIONS 
 
The present study provides novel evidence about the regulation of MAO activity 
upon conditions of oxidative stress in the heart. 
Here we proved for the first time that the increased availability of substrates 
plays a pivotal role in promoting MAO-dependent ROS production. Indeed, MAO 
inhibition causes accumulation of its substrates, especially NMH, in hearts 
subjected to ex vivo protocols of oxidative stress (H2O2 and IR). In parallel, ROS 
measurements showed also that MAO inhibition prevent cardiac damage 
indicating its implication in cardiac oxidative stress, as previously 
demonstrated.29, 119 Therefore, it is likely that under pathological conditions a 
larger availability of substrates fuels MAO activity, increasing the formation of 
H2O2 that might amplify an initial oxidative stress. 
Importantly, these results highlight for the first time a relationship between MAO 
activity and HA metabolism, that we had further confirmed by in vitro study in 
isolated cardiomyocytes.  
HA is a low molecular weight amine (111.15g/mol) that acts as a 
neurotransmitter. It mediates intercellular signals promoting different 
physiological processes through its specific four G protein-coupled receptors 
(H1, H2, H3 and H4).206, 207 Previous investigations have shown that endogenous 
HA and HA-receptors play highly significant roles in many cardiovascular 
diseases, such as hypertension,208, 209 artherosclerosis210, 211 and chronic heart 
failure.212, 213 Additionally, some reports found that cardiac HA and its receptors 
are important in the development of abnormal cardiac rhythms, especially those 
induced by post-ischemic reperfusion.214, 215, 216 However, no studies report any 
relation between HA metabolism and MAO activity in cardiac diseases. 
As described in the results, histidine-decarboxylase (HDC) synthesizes HA that is 
metabolized by histamine-N-methyltransferase (HNMT) to NMH. Both these 
enzymes are expressed in the whole heart. In particular, we showed for the first 
time that also isolated NRVMs are equipped of HDC and contain histamine and 
its catabolite.  
We also identified and evaluated the contribution of myocyte as MAO substrate 
source per se. We assessed that NRVMs actively participate to the oxidative 
stress induced by H2O2, through an increased availability of their substrates 
which amplify MAO activity.  
Then, incubating NRVMs with HA, we confirmed the relationship between MAO 
activity and HA metabolism. Indeed, HA entry in isolated cardiomyocytes 
promotes the induction of MAO activity after its transformation in NMH, that is a 
MAO substrate - at difference of histamine. Moreover, parallel ROS 
measurements demonstrated that HA treatment induced ROS increase, which 
was reduced upon MAO inhibition. 
To investigate the possible contribution of HA receptor-dependent signalling, we 
assessed the role of H2R in ROS increase upon HA exposure. The treatment of 
cardiomyocytes with famotidine, a H2R specific inhibitor, showed that ROS 
induction is not due to H2R-related pathway, a receptor-independent 
mechanism. 
Regarding non-myocyte sources, synaptic terminals deletion provided evidence 
of the pivotal role of catecholaminergic neurons in MAO substrate availability. 
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Indeed, chemical denervation significantly decreased NMH availability upon IR 
injury. Furthermore, parallel release of LDH showed a protective effect linked to 
denervation treatment, according to previous studies. This protection182, 184, 185 is 
likely to be linked to the reduction in MAO substrate availability and the 
consequent decrease in MAO activity. 
The significant increase of NMH upon MAO inhibition in denervated hearts 
subjected to IR protocol indicates that other sources besides synaptic terminals 
can contribute to MAO activity. These alternative sources can be represented by 
immune cells (mast cells, monocytes, macrophages, neutrophils) and/or by 
cardiomyocytes, as already suggested.  
On the other hand HA content was not significantly decreased by the deletion of 
catecholaminergic neurons. This can be explained by considering that HA is 
stored also in other cells of the heart, such as mast cells, which are resident in 
the tissue182 or cardiomyocytes and these non-neuronal cells are likely not to be 
affected by chemical denervation.  
Taken together, these data indicate that MAO substrates represent key 
regulators of MAO activity, highlighting an unexpected relationship between HA 
metabolism and MAO during cardiac damage. Importantly, we demonstrated the 
relevant contribution of (i) synaptic terminals as the main non-myocyte source 
and (ii) isolated cardiomyocytes. These results better define the mechanism 
through which MAO contributes to ROS formation upon cardiac injury, not only 
focusing on the intracellular enzyme but considering the environment and the 
intercellular interactions. Furthermore, our data support the relevant efficacy of 
MAO inhibitors in preventing increase oxidative stress and apoptosis in cardiac 
disease. Major advantages are given by MAO defined molecular structure, 
specific substrates, and clinically available inhibitors.148 Moreover, MAO 
inhibitors are specific and not toxic in comparison to most common drugs for 
heart disease as beta-blockers, statin and calcium channel blocker. 
In the second part of this work we better characterized MAO expression and role 
in human MΦ. Starting from the comparison between the pro- and anti-
inflammatory MΦ phenotype (M1 and M2 respectively) we showed that both the 
isoforms are expressed in M1 and M2 MΦ either. According to several papers, 
only isoform A displayed significant levels in M2 phenotype 106, 107, 108 so we 
focused our attention on this isoform in M2 MΦ. Next, we showed that also a pro-
inflammatory stimulus as LPS, commonly used to M1 MΦ polarization, induces 
MAO-A expression in M2 MΦ. Therefore we compared LPS to IL-4+IL-13 
treatment. By this comparison we uncovered a novel pathway of MAO induction. 
Both the inhibitors for p38MAPK and Sp1 transcription factors reduced MAO-A 
expression, providing new evidence that LPS and IL-4+IL-13 treatments 
converge to a common induction pathway, despite their contrasting nature. 
These observations highlight the plasticity of phagocytic cells to respond to 
different stimuli and underline the difficulty to strictly classify them in distinct 
subtypes, as recently suggested.67 
The effect of MAO inhibition on M-CSF dependent ROS production and induced 
ERK activity, demonstrated the involvement of MAO in the differentiation 
process of M2 MΦ. Moreover, we observed that MAO inhibition reduces CD163 
expression in M2 MΦ, indicating that pargyline inhibits the correct M2 
phenotype differentiation.  
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We also provided evidence of MAO contribution to ROS formation upon LPS 
treatment, suggesting that MAO is also involved in M2 MΦ polarization, whereas 
it is not in M1 MΦ polarization. ELISA assays for IL-10 and IL-6 supported the 
previous observations. Indeed, both IL-10 and IL-6 cytokines significantly 
decreased in the presence of pargyline upon 3h LPS exposure, indicating a direct 
contribution of MAO-dependent ROS formation.  
Taken together these results, in human samples, point out new insights of MAO 
activity in phagocytic cells. We demonstrated that MAO is not only important for 
amine degradation but it contributes to M2 MΦ differentiation and polarization 
by its product H2O2. These results suggest the possibility to consider MAO as a 
pharmacological target to modulate MΦ differentiation and polarization, in 
particular upon pathological conditions. Indeed, it is well known how M2 MΦ are 
involved in fibrosis, cardiovascular remodelling, IR injury,68, 101 as well as 
tumoral environment.217 Thus, the possibility to modulate MΦ activity and 
differentiation can represent a great advantage to reduce inflammation-
dependent damages upon pathological conditions. 
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